<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="men2" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">men2</book-part-id>
      <title-group>
        <title>Multiple Endocrine Neoplasia Type 2</title>
        <alt-title alt-title-type="alt-title">Synonyms: MEN 2, MEN2 Syndrome</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marquard</surname>
            <given-names>Jessica</given-names>
          </name>
          <degrees>MS, LGC</degrees>
          <aff>Genomic Medicine Institute<break/>Cleveland Clinic<break/>Cleveland, Ohio</aff>
          <email>marquaj2@ccf.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eng</surname>
            <given-names>Charis</given-names>
          </name>
          <degrees>MD, PhD, FACP</degrees>
          <aff>Genomic Medicine Institute<break/>Cleveland Clinic<break/>Department of Genetics and Genome Sciences<break/>Case Western Reserve University School of Medicine<break/>Cleveland, Ohio</aff>
          <email>engc@ccf.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>27</day>
          <month>9</month>
          <year>1999</year>
        </date>
        <date date-type="updated">
          <day>25</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="revised">
          <day>19</day>
          <month>5</month>
          <year>2004</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="men1" document-type="chapter">Multiple Endocrine Neoplasia Type 1</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="edm-ad" document-type="chapter">Multiple Epiphyseal Dysplasia, Autosomal Dominant</related-object>
      <abstract id="men2.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Multiple endocrine neoplasia type 2 (MEN 2) is classified into three subtypes: MEN 2A, FMTC (familial medullary thyroid carcinoma), and MEN 2B. All three subtypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B have an increased risk for pheochromocytoma; MEN 2A has an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a &#x02018;marfanoid&#x02019; habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of MEN 2 is established in a proband who fulfills existing diagnostic clinical criteria. Molecular genetic testing to identify a heterozygous germline <italic toggle="yes">RET</italic> pathogenic variant is indicated in all individuals with a diagnosis of primary C-cell hyperplasia or MTC or a clinical diagnosis of MEN 2. Identification of a heterozygous germline <italic toggle="yes">RET</italic> pathogenic variant on molecular genetic testing establishes the diagnosis if clinical features are inconclusive.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment for MTC is surgical removal of the thyroid gland and lymph node dissection. External beam radiation therapy (EBRT) or intensity-modulated radiation therapy (IMRT) can be considered for advanced locoregional disease. Kinase inhibitors may be used in metastatic MTC. Pheochromocytomas detected by biochemical testing and radionuclide imaging are removed by adrenalectomy. Primary hyperparathyroidism is treated with surgery to remove one or more parathyroid glands, or more rarely, medications to reduce parathyroid hormone secretion.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Prophylactic thyroidectomy for individuals with an identified germline <italic toggle="yes">RET</italic> pathogenic variant.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Prior to any surgery in an individual with MEN 2A or MEN 2B, the presence of a functioning pheochromocytoma should be excluded by appropriate biochemical screening.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual measurement of serum calcitonin concentration to detect residual or recurrent MTC after thyroidectomy, even if thyroidectomy was performed prior to biochemical evidence of disease. Monitoring for possible hypoparathyroidism in all those who have undergone thyroidectomy and parathyroid autotransplantation. Annual biochemical screening for those with a germline <italic toggle="yes">RET</italic> pathogenic variant whose initial screening results are negative for pheochromocytoma.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Dopamine D<sub>2</sub> receptor antagonists and &#x003b2;-adrenergic receptor antagonists present a high risk for adverse reactions in individuals with pheochromocytoma.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic>
<italic toggle="yes">RET</italic> molecular genetic testing should be offered to all at-risk members of kindreds in which a germline <italic toggle="yes">RET</italic> pathogenic variant has been identified.</p>
          <p><italic toggle="yes">Pregnancy management</italic>: Women with MEN 2 should be screened for pheochromocytoma prior to a planned pregnancy, or as early as possible during an unplanned pregnancy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>All MEN 2 subtypes are inherited in an autosomal dominant manner. The probability of a <italic toggle="yes">de novo</italic> pathogenic variant is 5% or less in index cases with MEN 2A and 50% in index cases with MEN 2B. Offspring of affected individuals have a 50% chance of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible if the <italic toggle="yes">RET</italic> pathogenic variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="men2.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="men2.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_men2.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Multiple Endocrine Neoplasia Type 2: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_men2.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Multiple endocrine neoplasia type 2A (MEN 2A)</p></list-item><list-item><p>Familial medullary thyroid carcinoma (FMTC)</p></list-item><list-item><p>Multiple endocrine neoplasia type 2B (MEN 2B)</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="men2.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="men2.Diagnosis">
        <title>Diagnosis</title>
        <sec id="men2.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Multiple endocrine neoplasia type 2 (MEN 2) includes the phenotypes MEN 2A, familial medullary thyroid carcinoma (FMTC), and MEN 2B.</p>
          <p><bold>MEN 2A</bold>
<bold>should be suspected</bold> in individuals with one or more specific endocrine tumors - medullary thyroid carcinoma (MTC), pheochromocytoma, or parathyroid adenoma/hyperplasia.</p>
          <p><bold>FMTC</bold>
<bold>should be suspected</bold> in families with more than one individual diagnosed with MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia.</p>
          <p><bold>MEN 2B</bold>
<bold>should be suspected</bold> in individuals with distinctive facies including lip mucosal neuromas resulting in thick vermilion of the upper and lower lip, mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, marfanoid habitus, and MTC.</p>
          <sec id="men2.Histologic_Biochemical_andor_Imagin">
            <title>Histologic, Biochemical, and/or Imaging Findings Suggestive Of MEN 2</title>
            <p>
              <bold>Medullary thyroid carcinoma (MTC) and C-cell hyperplasia (CCH)</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Histologic.</bold> MTC originates in calcitonin-producing cells (C-cells) of the thyroid gland. MTC is diagnosed histologically when nests of C-cells appear to extend beyond the basement membrane and to infiltrate and destroy thyroid follicles. Immunohistochemistry for calcitonin expression may be performed as a pathologic diagnostic adjunct.</p>
                <p>CCH is diagnosed histologically by the presence of an increased number of diffusely scattered or clustered C-cells. In MEN 2, the age of transformation from CCH to MTC varies with different germline <italic toggle="yes">RET</italic> pathogenic variants [<xref ref-type="bibr" rid="men2.REF.machens.2003.1517">Machens et al 2003</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Biochemical.</bold> MTC and CCH are suspected in the presence of an elevated plasma calcitonin concentration, a specific and sensitive marker. In provocative testing, plasma calcitonin concentration is measured before (basal level) and two and five minutes after intravenous administration of calcium (stimulated level). Other calcitonin secretagogues such as pentagastrin (available in Europe, limited in the US) are also used. A basal or stimulated calcitonin level of &#x02265;100 pg/mL is an indication for surgery [<xref ref-type="bibr" rid="men2.REF.costante.2007.450">Costante et al 2007</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
              </list-item>
            </list>
            <p>
              <bold>Pheochromocytoma</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Biochemical.</bold> Pheochromocytoma is suspected when biochemical screening reveals elevated excretion of catecholamines and catecholamine metabolites (e.g., norepinephrine, epinephrine, metanephrine, and vanillylmandelic acid [VMA]) in plasma or 24-hour urine collections [<xref ref-type="bibr" rid="men2.REF.pacak.2005.60">Pacak et al 2005</xref>, <xref ref-type="bibr" rid="men2.REF.ilias.2009.89">Ilias &#x00026; Pacak 2009</xref>]. In MEN 2, pheochromocytomas consistently produce epinephrine or epinephrine and norepinephrine [<xref ref-type="bibr" rid="men2.REF.ilias.2009.89">Ilias &#x00026; Pacak 2009</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Imaging.</bold> Abdominal MRI and/or CT are performed if plasma or urinary catecholamine values are increased or if a pheochromocytoma is suspected clinically. MRI is more sensitive than CT in detection of a pheochromocytoma.</p>
                <p>[<sup>18</sup>F]-fluorodopamine ([<sup>18</sup>F]DA) PET is the best overall imaging modality in the localization of pheochromocytomas. If [<sup>18</sup>F]DA PET is unavailable, MIBG (<sup>123</sup>I- or <sup>131</sup>I- metaiodobenzylguanidine) scintigraphy should be used to further evaluate individuals with biochemical or radiographic evidence of pheochromocytoma [<xref ref-type="bibr" rid="men2.REF.ilias.2008.1613">Ilias et al 2008</xref>].</p>
              </list-item>
            </list>
            <p>
              <bold>Parathyroid abnormalities</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Biochemical.</bold> Parathyroid abnormalities are present when elevated serum calcium occurs simultaneously with elevated or high-normal parathyroid hormone (PTH).</p>
              </list-item>
              <list-item>
                <p><bold>Imaging.</bold> Postoperative parathyroid localizing studies with <sup>99m</sup>Tc-sestamibi scintigraphy may be helpful if hyperparathyroidism recurs. For preoperative adenoma localization, three-dimensional single-photon emission CT (SPECT) may also be used [<xref ref-type="bibr" rid="men2.REF.brenner.2008.1117">Brenner &#x00026; Jacene 2008</xref>].</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="men2.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of MEN 2 <bold>is established</bold> in a proband with the following clinical criteria. Identification of a heterozygous germline <italic toggle="yes">RET</italic> pathogenic variant on molecular genetic testing establishes the diagnosis if clinical features are inconclusive.</p>
          <p>
            <bold>Clinical criteria</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>MEN 2A is diagnosed clinically by the occurrence of two or more specific endocrine tumors (medullary thyroid carcinoma [MTC], pheochromocytoma, or parathyroid adenoma/hyperplasia) in a single individual or in close relatives.</p>
            </list-item>
            <list-item>
              <p>Familial medullary thyroid carcinoma (FMTC) is diagnosed in families with four or more cases of MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia.</p>
            </list-item>
            <list-item>
              <p>MEN 2B is diagnosed clinically by the presence of early-onset MTC, mucosal neuromas of the lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, and an asthenic &#x02018;marfanoid&#x02019; body habitus [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
            </list-item>
          </list>
          <p><bold>Molecular genetic testing</bold> to identify a heterozygous germline <italic toggle="yes">RET</italic> pathogenic variant is indicated in all individuals with a diagnosis of primary C-cell hyperplasia or MTC or a clinical diagnosis of MEN 2. The algorithm for testing is summarized in the most recent <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.liebertonline.com/doi/abs/10.1089/thy.2008.0403">American Thyroid Association MTC Practice Guidelines</ext-link> [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. Note: If clinical findings suggest a diagnosis of MEN 2 in an individual with no family history of the disorder, molecular genetic testing of <italic toggle="yes">RET</italic> is still indicated.</p>
          <p>Molecular testing approaches can include <bold>select exon testing</bold>, <bold>single-gene testing</bold>, and use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Select exon testing.</bold> The majority of pathogenic variants occur in exons 10, 11, and 13-16. Sequence analysis of select exons and targeted analysis for pathogenic variants may be offered by some laboratories.</p>
            </list-item>
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">RET</italic> may be performed if no pathogenic variant is found by select exon testing.</p>
              <p>Note: Since MEN 2 occurs through a gain of function mechanism and large intragenic deletion or duplication has not been reported, testing for intragenic deletions or duplications is not indicated.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">RET</italic> and other genes of interest (see <xref ref-type="sec" rid="men2.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered, especially in the case of isolated or familial pheochromocytoma. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="men2.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in MEN 2</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2">Test Method&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>3</sup> Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">MEN 2A</th>
                  <th headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">FMTC</th>
                  <th headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">MEN 2B</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">RET</italic>
                  </td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;98%&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>6,&#x000a0;7</sup></td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;98%&#x000a0;<sup>8</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of select exons</td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">98%&#x000a0;<sup>5,&#x000a0;9</sup></td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">95%&#x000a0;<sup>6,&#x000a0;7</sup></td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>10</sup></td>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">98%&#x000a0;<sup>8</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="men2.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="men2" object-id="men2.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="men2.TF.1.2">
                <label>2. </label>
                <p>Since MEN 2 occurs through a gain of function mechanism, gene-targeted deletion/duplication analysis to detect intragenic deletions or duplications is not indicated. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="men2.TF.1.3">
                <label>3. </label>
                <p>See <xref ref-type="sec" rid="men2.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="men2.TF.1.4">
                <label>4. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="men2.TF.1.5">
                <label>5. </label>
                <p><xref ref-type="bibr" rid="men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan [2000]</xref>, <xref ref-type="bibr" rid="men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng [2007]</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force [2009]</xref></p>
              </fn>
              <fn id="men2.TF.1.6">
                <label>6. </label>
                <p><xref ref-type="bibr" rid="men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan [2000]</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force [2009]</xref></p>
              </fn>
              <fn id="men2.TF.1.7">
                <label>7. </label>
                <p>Pathogenic variants of codons 618, 620, and 634 each account for 20% to 30% of pathogenic variants. Other pathogenic variants in exons 5, 8, 10, 11, and 13 to 16 appear to account for a small percentage of pathogenic variants in families with FMTC, with an important minority affecting codons 768 and 804.</p>
              </fn>
              <fn id="men2.TF.1.8">
                <label>8. </label>
                <p>Approximately 95% of individuals have a pathogenic variant at codon 918 in exon 16 [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>]. A pathogenic variant in exon 15 has been identified in several affected individuals [<xref ref-type="bibr" rid="men2.REF.gimm.1997.3902">Gimm et al 1997</xref>, <xref ref-type="bibr" rid="men2.REF.smith.1997.1213">Smith et al 1997</xref>].</p>
              </fn>
              <fn id="men2.TF.1.9">
                <label>9. </label>
                <p>Pathogenic variants in exons 10 and 11 [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]</p>
              </fn>
              <fn id="men2.TF.1.10">
                <label>10. </label>
                <p>Pathogenic variants typically detected: p.Met918Thr, p.Ala883Phe. Note: Pathogenic variants included in a panel may vary by laboratory.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v20/n1/full/ejhg2011142a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="men2.REF.raue.2012.20">Raue et al 2012</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="men2.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="men2.Clinical_Description">
          <title>Clinical Description</title>
          <p>The endocrine disorders observed in multiple endocrine neoplasia type 2 (MEN 2) are: medullary thyroid carcinoma (MTC) and/or its precursor, C-cell hyperplasia; pheochromocytoma; and parathyroid adenoma or hyperplasia.</p>
          <p><bold>MTC</bold> in persons with MEN 2 typically presents at a younger age than sporadic MTC and is more often associated with C-cell hyperplasia as well as multifocality or bilaterality. Symptoms of MTC include neck pain, a palpable neck mass, and/or diarrhea resulting from hypercalcitoninemia [<xref ref-type="bibr" rid="men2.REF.callender.2008.863">Callender et al 2008</xref>]. Metastatic spread to cervical and regional lymph nodes (i.e., parathyroid, paratracheal, jugular chain, and upper mediastinum) or to distant sites including the liver, lungs, or bone is common and has often occurred in individuals with a palpable thyroid mass or diarrhea [<xref ref-type="bibr" rid="men2.REF.moley.1998.521">Moley et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</xref>]. About 25%-30% of all individuals with MTC have a germline <italic toggle="yes">RET</italic> pathogenic variant. In a large series of individuals with simplex medullary thyroid carcinoma (i.e., no known family history of MTC or personal history of other endocrine disease), approximately 7% were found to have a germline <italic toggle="yes">RET</italic> pathogenic variant [<xref ref-type="bibr" rid="men2.REF.elisei.2007.4725">Elisei et al 2007</xref>].</p>
          <p><bold>Pheochromocytomas</bold> in individuals with MEN 2 are nearly always adrenal and often bilateral [<xref ref-type="bibr" rid="men2.REF.pomares.1998.195">Pomares et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.pacak.2005.60">Pacak et al 2005</xref>, <xref ref-type="bibr" rid="men2.REF.thosani.2013.e1813">Thosani et al 2013</xref>].</p>
          <p>Individuals with a confirmed germline <italic toggle="yes">RET</italic> pathogenic variant who present with head and neck paraganglioma all have a personal and/or family history consistent with MEN 2 [Boedeker CC et al 2009].</p>
          <p>Although pheochromocytomas in individuals with MEN 2 rarely metastasize, they can be lethal because of intractable hypertension or anesthesia-induced hypertensive crises.</p>
          <p><bold>Parathyroid abnormalities</bold> can range from benign parathyroid adenomas to clinically evident hyperparathyroidism with hypercalcemia and renal stones.</p>
          <p>MEN 2 is classified into three clinical subtypes: MEN 2A, FMTC, and MEN 2B (<xref ref-type="table" rid="men2.T.percent_of_clinical_features_by_m">Table 2</xref>). All three subtypes involve high risk for MTC; individuals with MEN 2A and MEN 2B are at increased risk for pheochromocytoma; individuals with MEN 2A are at increased risk for parathyroid hyperplasia or adenoma. Classifying an individual or family by MEN 2 subtype is useful for determining prognosis and management.</p>
          <table-wrap id="men2.T.percent_of_clinical_features_by_m" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Percent of Clinical Features by MEN 2 Subtype</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Subtype</th>
                  <th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Medullary Thyroid Carcinoma</th>
                  <th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pheochromocytoma</th>
                  <th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Parathyroid Disease</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>MEN 2A</bold>
                  </td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">95%</td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%</td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">20%-30%</td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>FMTC</bold>
                  </td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">0%</td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">0%</td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>MEN 2B</bold>
                  </td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">50%</td>
                  <td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Uncommon</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <sec id="men2.MEN_2A">
            <title>MEN 2A</title>
            <p>The MEN 2A subtype constitutes approximately 70%-80% of cases of MEN 2. Since genetic testing for <italic toggle="yes">RET</italic> pathogenic variants has become available, it has become apparent that 95% of individuals with MEN 2A develop MTC, about 50% develop pheochromocytoma, and about 20%-30% develop hyperparathyroidism [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>].</p>
            <p>MTC is generally the first manifestation of MEN 2A. Probands with MTC typically present with a neck mass or neck pain prior to age 35 years. Up to 70% of such individuals already have cervical lymph node metastases [<xref ref-type="bibr" rid="men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</xref>]. Diarrhea (the most frequent systemic symptom) occurs in affected individuals with a plasma calcitonin concentration &#x0003e;10 ng/mL and implies a poor prognosis. All individuals with an MTC-predisposing pathogenic variant who have not undergone prophylactic thyroidectomy demonstrate biochemical evidence of MTC by age 35 years [<xref ref-type="bibr" rid="men2.REF.delellis.2004">DeLellis et al 2004</xref>].</p>
            <p>Pheochromocytomas usually present after MTC or concomitantly; however, they are the first sign in 13%-27% of individuals with MEN 2A [<xref ref-type="bibr" rid="men2.REF.inabnet.2000.1007">Inabnet et al 2000</xref>, <xref ref-type="bibr" rid="men2.REF.rodriguez.2008.2520">Rodriguez et al 2008</xref>]. Pheochromocytomas in persons with MEN 2A are diagnosed at an earlier age, have subtler symptoms, and are more likely to be bilateral than sporadic tumors [<xref ref-type="bibr" rid="men2.REF.pomares.1998.195">Pomares et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.pacak.2005.60">Pacak et al 2005</xref>]. Malignant transformation occurs in about 4% of cases [<xref ref-type="bibr" rid="men2.REF.modigliani.1995.363">Modigliani et al 1995</xref>]. Since pheochromocytoma can be the first manifestation of MEN 2A, the diagnosis of pheochromocytoma in an individual warrants further investigation for MEN 2A [<xref ref-type="bibr" rid="men2.REF.inabnet.2000.1007">Inabnet et al 2000</xref>, <xref ref-type="bibr" rid="men2.REF.neumann.2002.1459">Neumann et al 2002</xref>].</p>
            <p>Hyperparathyroidism (HPT) in MEN 2A is typically mild and may range from a single adenoma to marked hyperplasia. Most individuals with hyperparathyroidism have no symptoms; however, hypercalciuria and renal calculi may occur [<xref ref-type="bibr" rid="men2.REF.brandi.2001.5658">Brandi et al 2001</xref>]. HPT usually presents many years after the diagnosis of MTC; the average age at onset is 38 years [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
            <p>A small number of families with MEN 2A have pruritic cutaneous lichen amyloidosis (PCLA), also known as cutaneous lichen amyloidosis (CLA). This lichenoid skin lesion is located over the upper portion of the back and may appear before the onset of MTC [<xref ref-type="bibr" rid="men2.REF.seri.1997.86">Seri et al 1997</xref>].</p>
          </sec>
          <sec id="men2.FMTC">
            <title>FMTC</title>
            <p>The FMTC subtype constitutes approximately 10%-20% of cases of MEN 2. By operational definition MTC is the only clinical manifestation of FMTC. The age of onset of MTC is later in FMTC and the penetrance of MTC is lower than that observed in MEN 2A and MEN 2B [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>, <xref ref-type="bibr" rid="men2.REF.machens.2001.1104">Machens et al 2001</xref>, <xref ref-type="bibr" rid="men2.REF.machens.2006.34">Machens &#x00026; Dralle 2006</xref>, <xref ref-type="bibr" rid="men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. To avoid erroneously disregarding a risk for pheochromocytoma, strict criteria should be met before a family is classified as having FMTC. In the past, some believed that a kindred with FMTC should have more than ten members with a <italic toggle="yes">RET</italic> pathogenic variant and multiple individuals with a <italic toggle="yes">RET</italic> pathogenic variant over age 50 years, and all members should have an adequate medical history demonstrating absence of pheochromocytoma or hyperparathyroidism [<xref ref-type="bibr" rid="men2.REF.brandi.2001.5658">Brandi et al 2001</xref>].</p>
            <p>Today, FMTC is typically viewed as a variant of MEN 2A with decreased penetrance of pheochromocytoma and hyperparathyroidism, rather than a distinct subtype [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          </sec>
          <sec id="men2.MEN_2B">
            <title>MEN 2B</title>
            <p>The MEN 2B subtype accounts for approximately 5% of cases of MEN 2. MEN 2B is characterized by the early development of an aggressive form of MTC in all affected individuals [<xref ref-type="bibr" rid="men2.REF.skinner.1996.177">Skinner et al 1996</xref>]. Individuals with MEN 2B who do not undergo thyroidectomy before age one year are likely to develop metastatic MTC at an early age. Prior to intervention with early prophylactic thyroidectomy, the average age of death in individuals with MEN 2B was 21 years.</p>
            <p>Pheochromocytomas occur in 50% of individuals with MEN 2B; about half are multiple and often bilateral. Individuals with undiagnosed pheochromocytoma may die from a cardiovascular hypertensive crisis perioperatively.</p>
            <p>Clinically significant parathyroid disease is absent in MEN 2B.</p>
            <p>Individuals with MEN 2B may be identified in infancy or early childhood by the presence of mucosal neuromas on the anterior dorsal surface of the tongue, palate, or pharynx and a distinctive facial appearance. The lips become prominent (or &#x02018;blubbery&#x02019;) over time, and submucosal nodules may be present on the vermilion border of the lips. Neuromas of the eyelids may cause thickening and eversion of the upper eyelid margins. Prominent thickened corneal nerves may be seen by slit lamp examination.</p>
            <p>About 40% of affected individuals have diffuse ganglioneuromatosis of the gastrointestinal tract. Associated symptoms include abdominal distension, megacolon, constipation, or diarrhea. In one study of 19 individuals with MEN 2B, 84% reported gastrointestinal symptoms beginning in infancy or early childhood [<xref ref-type="bibr" rid="men2.REF.wray.2008.293">Wray et al 2008</xref>].</p>
            <p>About 75% of affected individuals have a marfanoid habitus, often with kyphoscoliosis or lordosis, joint laxity, and decreased subcutaneous fat. Proximal muscle wasting and weakness can also be seen.</p>
          </sec>
        </sec>
        <sec id="men2.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Pathogenic variants involving the cysteine codons 609, 618, and 620 in exon 10 of <italic toggle="yes">RET</italic> are associated with MEN 2A, FMTC, and HSCR1 [<xref ref-type="bibr" rid="men2.REF.mulligan.1994.2163">Mulligan et al 1994</xref>, <xref ref-type="bibr" rid="men2.REF.decker.1998.129">Decker et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.romeo.1998.515">Romeo et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.inoue.1999.1552">Inoue et al 1999</xref>, <xref ref-type="bibr" rid="men2.REF.takahashi.1999.331">Takahashi et al 1999</xref>]. A pathogenic variant in one of these codons, is detected in about 10% of families with MEN 2A and more than 50% of families with FMTC; these pathogenic variants are associated with low transforming activity of <italic toggle="yes">RET</italic> [<xref ref-type="bibr" rid="men2.REF.takahashi.1998.509">Takahashi et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan 2000</xref>].</p>
          <p><italic toggle="yes">RET</italic> germline pathogenic variant, p.Met918Thr, is only associated with MEN 2B; however, somatic pathogenic variants at this codon are frequently observed in MTC in individuals with no known family history of MTC, and are over-represented in individuals with sporadic MTC who have a particular germline <italic toggle="yes">RET</italic> variant, c.2439C&#x0003e;T (p.Ser836Ser) [<xref ref-type="bibr" rid="men2.REF.gimm.1999.1369">Gimm et al 1999</xref>].</p>
          <p>Any <italic toggle="yes">RET</italic> pathogenic variant at codon 634 in exon 11 results in a higher incidence of pheochromocytomas and hyperparathyroidism [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>, <xref ref-type="bibr" rid="men2.REF.yip.2003.409">Yip et al 2003</xref>, <xref ref-type="bibr" rid="men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>A report of 12 Brazilian families indicated that p.Cys634Arg is associated with a higher probability of having metastases at diagnosis than other codon 634 pathogenic variants [<xref ref-type="bibr" rid="men2.REF.pu_ales.2003.2644">Pu&#x000f1;ales et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>Codon 634 pathogenic variants are also associated with development of cutaneous lichen amyloidosis [<xref ref-type="bibr" rid="men2.REF.seri.1997.86">Seri et al 1997</xref>]. Among 25 individuals from three families with a codon 634 pathogenic variant, 36% had cutaneous lichen amyloidosis [<xref ref-type="bibr" rid="men2.REF.verga.2003.156">Verga et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>While 25% of FMTC kindreds harbor a pathogenic variant in codon 634, p.Cys634Arg pathogenic variants are virtually absent in this subtype [<xref ref-type="bibr" rid="men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan 2000</xref>, <xref ref-type="bibr" rid="men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>].</p>
            </list-item>
          </list>
          <p>Pathogenic variants at codons 768, 804, and 891 that were initially only associated with MTC have subsequently been found in families with MEN 2A [<xref ref-type="bibr" rid="men2.REF.jimenez.2004a.3521">Jimenez et al 2004a</xref>, <xref ref-type="bibr" rid="men2.REF.aiello.2005.574">Aiello et al 2005</xref>, <xref ref-type="bibr" rid="men2.REF.schulte.2010.e92">Schulte et al 2010</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Initially thought to be associated with MTC only, pathogenic variants at codon 804 in exon 14 (e.g., p.Val804Leu and p.Val804Met) were subsequently identified in individuals with pheochromocytoma [<xref ref-type="bibr" rid="men2.REF.nilsson.1999.1587">Nilsson et al 1999</xref>, <xref ref-type="bibr" rid="men2.REF.h_ie.2000.3249">H&#x000f8;ie et al 2000</xref>, <xref ref-type="bibr" rid="men2.REF.gibelin.2004.1458">Gibelin et al 2004</xref>, <xref ref-type="bibr" rid="men2.REF.jimenez.2004a.3521">Jimenez et al 2004a</xref>].</p>
            </list-item>
            <list-item>
              <p>Disease expression of pathogenic variants at codon 804 has been shown to be highly variable, even within the same family [<xref ref-type="bibr" rid="men2.REF.feldman.2000.93">Feldman et al 2000</xref>, <xref ref-type="bibr" rid="men2.REF.frohnauer.2000.1052">Frohnauer &#x00026; Decker 2000</xref>]. Some individuals with such pathogenic variants have MTC at age five years and fatal metastatic MTC at age 12 years, whereas other individuals with the same pathogenic variant have been shown to have normal thyroid histology at age 27 years, normal biochemical screening at age 40 years, and no clinical evidence of MTC at age 86 years.</p>
            </list-item>
            <list-item>
              <p>In another large family with a high level of consanguinity, biochemical testing indicated expression of thyroid disease in individuals homozygous but not heterozygous for p.Val804Met [<xref ref-type="bibr" rid="men2.REF.lecube.2002.509">Lecube et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Cutaneous lichen amyloidosis in the background of a p.Val804Met pathogenic variant has been reported in one individual [<xref ref-type="bibr" rid="men2.REF.rothberg.2009.651">Rothberg et al 2009</xref>].</p>
            </list-item>
          </list>
          <p>One study suggests that in addition to their association with MTC, pathogenic variants in codons 790 or 804 may be associated with papillary thyroid carcinoma [<xref ref-type="bibr" rid="men2.REF.brauckhoff.2002.557">Brauckhoff et al 2002</xref>]. In a large Italian family, 40% of family members with a p.Val804Met pathogenic variant who were examined in detail had concomitant medullary and papillary thyroid carcinoma [<xref ref-type="bibr" rid="men2.REF.shifrin.2009.998">Shifrin et al 2009</xref>].</p>
          <p>The American Thyroid Association Guidelines Task Force has classified pathogenic variants based on their risk for aggressive MTC [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>] (<xref ref-type="table" rid="men2.T.risk_for_aggressive_mtc_based_on">Table 3</xref>).</p>
          <p>The classification may be used in (1) predicting phenotype and in (2) recommendations regarding the ages at which to (a) perform prophylactic thyroidectomy and (b) begin biochemical screening for pheochromocytoma and hyperparathyroidism (see <xref ref-type="sec" rid="men2.Surveillance">Surveillance</xref>).</p>
          <table-wrap id="men2.T.risk_for_aggressive_mtc_based_on" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Risk for Aggressive MTC Based on Genotype</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">ATA&#x000a0;<sup>1</sup> Risk Level</th>
                  <th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants&#x000a0;<sup>2,&#x000a0;3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level D<break/>(highest risk)</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala883Phe<break/>p.Met918Thr<break/>p.Val804Met+p.Glu805Lys&#x000a0;<sup>4</sup><break/>p.Val804Met+p.Tyr806Cys&#x000a0;<sup>4</sup><break/>p.Val804Met+p.Ser904Cys&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level C</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys634Arg/Gly/Phe/Ser/Trp/Tyr</td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level B</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys609Phe/Arg/Gly/Ser/Tyr<break/>p.Cys611Arg/Gly/Phe/Ser/Trp/Tyr<break/>p.Cys618Arg/Gly/Phe/Ser/Tyr<break/>p.Cys620Arg/Gly/Phe/Ser/Trp/Tyr<break/>p.Cys630Arg/Phe/Ser/Tyr<break/>p.Asp631Tyr<break/>p.633/9 bp dup<break/>p.634/12 bp dup<break/>p.Val804Met+p.Val778Ile&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level A</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg321Gly<break/>p.531/9 bp dup<break/>p.532 dup<break/>p.Cys515Ser<break/>p.Gly533Cys<break/>p.Arg600Gln<break/>p.Lys603Glu<break/>p.Tyr606Cys<break/>p.635/insert ELCR;p.Thr636Pro<break/>p.Lys666Glu<break/>p.Glu768Asp<break/>p.Asn777Ser<break/>p.Leu790Phe<break/>p.Val804Leu/Met<break/>p.Gly819Lys<break/>p.Arg833Cys<break/>p.Arg844Gln<break/>p.Arg866Trp<break/>p.Ser891Ala<break/>p.Arg912Pro</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="men2.TF.3.1">
                <label>1. </label>
                <p>ATA = American Thyroid Association</p>
              </fn>
              <fn id="men2.TF.3.2">
                <label>2. </label>
                <p>p.Ser649Leu and p.Tyr791Phe have been removed from this list as they have been reclassified as polymorphisms [<xref ref-type="bibr" rid="men2.REF.erlic.2010.308">Erlic et al 2010</xref>].</p>
              </fn>
              <fn id="men2.TF.3.3">
                <label>3. </label>
                <p>Pathogenic variant designations have not been edited by <italic toggle="yes">GeneReviews</italic> staff and may not be standard nomenclature.</p>
              </fn>
              <fn id="men2.TF.3.4">
                <label>4. </label>
                <p>Pathogenic variants in <italic toggle="yes">cis</italic> configuration on one allele</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="men2.Penetrance">
          <title>Penetrance</title>
          <p>The penetrance for MTC, pheochromocytoma, and parathyroid disease varies by MEN 2 subtype (see <xref ref-type="table" rid="men2.T.percent_of_clinical_features_by_m">Table 2</xref>).</p>
        </sec>
        <sec id="men2.Nomenclature">
          <title>Nomenclature</title>
          <p>MEN 2A is also referred to as Sipple syndrome.</p>
          <p>Mucosal neuroma syndrome is a synonym for MEN 2B. MEN 2B was initially called Wagenmann-Froboese syndrome [<xref ref-type="bibr" rid="men2.REF.morrison.1996.779">Morrison &#x00026; Nevin 1996</xref>].</p>
        </sec>
        <sec id="men2.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of MEN 2 has been estimated at 1:35,000 [<xref ref-type="bibr" rid="men2.REF.delellis.2004">DeLellis et al 2004</xref>].</p>
        </sec>
      </sec>
      <sec id="men2.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold>HSCR1.</bold> Germline <italic toggle="yes">RET</italic> pathogenic variants are associated with HSCR1. <related-object link-type="booklink" source-id="gene" document-id="hirschsprung-ov" document-type="chapter">Hirschsprung disease</related-object> (HSCR) is a disorder of the enteric plexus of the colon that typically results in enlargement of the bowel and constipation or obstipation in neonates. About 50% of familial cases and 35% of simplex cases (i.e., a single occurrence in a family) of HSCR are caused by a heterozygous germline loss-of-function pathogenic variant in the <italic toggle="yes">RET</italic> proto-oncogene and are designated HSCR1 [<xref ref-type="bibr" rid="men2.REF.kouvaraki.2005.531">Kouvaraki et al 2005</xref>]. Germline pathogenic variants causing HSCR occur throughout the coding sequence of <italic toggle="yes">RET</italic> [<xref ref-type="bibr" rid="men2.REF.takahashi.1999.331">Takahashi et al 1999</xref>]. Families and individuals with a germline <italic toggle="yes">RET</italic> pathogenic variant in exon 10, especially affecting codons 618 and 620, often cosegregate MEN 2A/FMTC and HSCR [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
      </sec>
      <sec id="men2.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>MTC in individuals with no family history of MTC.</bold> Medullary thyroid carcinoma accounts for approximately 10% of new cases of thyroid cancer diagnosed annually in the US. Sporadic MTC tends to be unifocal, occur at a later age of onset, and lack C-cell hyperplasia (CCH) [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
        <p>DNA analysis of MTC tissue revealed a 40%-50% incidence of somatic <italic toggle="yes">RET</italic> pathogenic variants in the absence of a germline pathogenic variant [<xref ref-type="bibr" rid="men2.REF.schilling.2001.62">Schilling et al 2001</xref>, <xref ref-type="bibr" rid="men2.REF.de_groot.2006.535">de Groot et al 2006</xref>, <xref ref-type="bibr" rid="men2.REF.dvorakova.2008.21">Dvorakova et al 2008</xref>, <xref ref-type="bibr" rid="men2.REF.elisei.2008.682">Elisei et al 2008</xref>]. The p.Met918Thr pathogenic variant is the most common; pathogenic variants at other codons as well as small in-frame deletions have been reported [<xref ref-type="bibr" rid="men2.REF.de_groot.2006.535">de Groot et al 2006</xref>]. Tumors with a somatic codon 918 pathogenic variant appear to be more aggressive [<xref ref-type="bibr" rid="men2.REF.schilling.2001.62">Schilling et al 2001</xref>, <xref ref-type="bibr" rid="men2.REF.elisei.2008.682">Elisei et al 2008</xref>].</p>
        <p><bold>C-cell hyperplasia (CCH).</bold> CCH associated with a positive calcitonin stimulation test occurs in about 5% of the general population. Serum calcitonin levels may be elevated in persons with chronic renal failure, sepsis, neuroendocrine tumors of the lung or gastrointestinal tract, hypergastrinemia, mastocytosis, autoimmune thyroid disease, and type 1A pseudohypoparathyroidism [<xref ref-type="bibr" rid="men2.REF.costante.2009.35">Costante et al 2009</xref>].</p>
        <p>Secondary CCH has been described occasionally in the setting of aging and hyperparathyroidism. Secondary CCH rarely transforms to MTC and is not related to MEN 2.</p>
        <p><bold>Pheochromocytoma.</bold> Up to 25% of individuals with pheochromocytoma and no known family history of pheochromocytoma have a heterozygous pathogenic variant in one of several genes: <italic toggle="yes">RET</italic>, <italic toggle="yes">VHL</italic>, <italic toggle="yes">SDHD</italic>, or <italic toggle="yes">SDHB</italic> [<xref ref-type="bibr" rid="men2.REF.neumann.2002.1459">Neumann et al 2002</xref>, <xref ref-type="bibr" rid="men2.REF.bryant.2003.1196">Bryant et al 2003</xref>, <xref ref-type="bibr" rid="men2.REF.neumann.2004.943">Neumann et al 2004</xref>]. Approximately 5% of individuals with nonsyndromic pheochromocytoma and no family history of pheochromocytoma were heterozygous for a <italic toggle="yes">RET</italic> pathogenic variant [<xref ref-type="bibr" rid="men2.REF.neumann.2002.1459">Neumann et al 2002</xref>].Other pheochromocytoma susceptibility genes including <italic toggle="yes">SDHC</italic>, <italic toggle="yes">TMEM127</italic>, <italic toggle="yes">MAX</italic>, and <italic toggle="yes">SDHA</italic> further expand the differential diagnosis for nonsyndromic paraganglioma and pheochromocytoma [<xref ref-type="bibr" rid="men2.REF.peczkowska.2008.111">Peczkowska et al 2008</xref>, <xref ref-type="bibr" rid="men2.REF.burnichon.2009.2817">Burnichon et al 2009</xref>, <xref ref-type="bibr" rid="men2.REF.bayley.2010.366">Bayley et al 2010</xref>, <xref ref-type="bibr" rid="men2.REF.burnichon.2010.3011">Burnichon et al 2010</xref>, <xref ref-type="bibr" rid="men2.REF.qin.2010.229">Qin et al 2010</xref>, <xref ref-type="bibr" rid="men2.REF.cominom_ndez.2011.663">Comino-M&#x000e9;ndez et al 2011</xref>, <xref ref-type="bibr" rid="men2.REF.vandy.2011.805">Vandy et al 2011</xref>]. An algorithm for prioritizing which gene(s) to test is outlined by <xref ref-type="bibr" rid="men2.REF.erlic.2009.6378">Erlic et al [2009]</xref>, <xref ref-type="bibr" rid="men2.REF.neumann.2009.3650">Neumann et al [2009]</xref>, and <xref ref-type="bibr" rid="men2.REF.welander.2011.r253">Welander et al [2011]</xref>. However, multi-gene panels may also be considered for individuals with no syndromic features.</p>
        <p>Evaluation of biochemical features can help differentiate MEN 2-associated pheochromocytoma. <xref ref-type="bibr" rid="men2.REF.pacak.2005.60">Pacak et al [2005]</xref> compared biochemical profiles for inherited and sporadic pheochromocytoma and found that MEN 2 can be ruled out in pheochromocytomas that exclusively produce normetanephrine.</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="vhl" document-type="chapter"><bold>VHL (von Hippel Lindau) syndrome</bold></related-object><bold>.</bold> Any individual presenting with a pheochromocytoma should be evaluated for von Hippel Lindau (VHL) syndrome [<xref ref-type="bibr" rid="men2.REF.erlic.2009.6378">Erlic et al 2009</xref>]. VHL syndrome is characterized by pheochromocytoma, renal cell carcinoma, cerebellar and spinal hemangioblastoma, and retinal angioma.</p>
            <p>Some families with apparent autosomal dominant pheochromocytoma have a germline <italic toggle="yes">VHL</italic> pathogenic variant in the absence of other clinical manifestations of VHL syndrome [<xref ref-type="bibr" rid="men2.REF.inabnet.2000.1007">Inabnet et al 2000</xref>]. <xref ref-type="bibr" rid="men2.REF.neumann.2002.1459">Neumann et al [2002]</xref> identified germline <italic toggle="yes">VHL</italic> pathogenic variants in 11% of individuals with nonsyndromic pheochromocytoma and no family history of pheochromocytoma. However, a US-based study found no pathogenic variants in <italic toggle="yes">VHL</italic> in individuals with nonsyndromic pheochromocytoma or paraganglioma [<xref ref-type="bibr" rid="men2.REF.fishbein.2013.1444">Fishbein et al 2013</xref>].</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="paragangliomas" document-type="chapter"><bold>Hereditary paraganglioma-pheochromocytoma syndrome</bold></related-object><bold>.</bold> Pathogenic variants in the succinate dehydrogenase genes <italic toggle="yes">SDHA, SDHB, SDHC, SDHD, and SDHAF2</italic> cause hereditary paraganglioma-pheochromocytoma syndrome. Early studies found that approximately 8.5% of individuals with apparently nonfamilial nonsyndromic pheochromocytoma have been shown to have a pathogenic variant in one of the genes (<italic toggle="yes">SDHD</italic> or <italic toggle="yes">SDHB</italic>) encoding the succinate dehydrogenase subunits that cause the hereditary paraganglioma-pheochromocytoma syndromes [<xref ref-type="bibr" rid="men2.REF.neumann.2002.1459">Neumann et al 2002</xref>, <xref ref-type="bibr" rid="men2.REF.neumann.2004.943">Neumann et al 2004</xref>]. While head and neck paragangliomas are common in individuals with hereditary paraganglioma-pheochromocytoma syndrome, they are extremely rare in MEN 2 [<xref ref-type="bibr" rid="men2.REF.boedeker.2009.1938">Boedeker et al 2009</xref>]. Although pathogenic variants in <italic toggle="yes">SDHC</italic> initially were thought to only cause head/neck paragangliomas, several cases of <italic toggle="yes">SDHC-</italic>associated pheochromocytoma have been reported in the literature [<xref ref-type="bibr" rid="men2.REF.peczkowska.2008.111">Peczkowska et al 2008</xref>, <xref ref-type="bibr" rid="men2.REF.burnichon.2009.2817">Burnichon et al 2009</xref>, <xref ref-type="bibr" rid="men2.REF.vandy.2011.805">Vandy et al 2011</xref>]. <xref ref-type="bibr" rid="men2.REF.korpershoek.2011.e1472">Korpershoek et al [2011]</xref> found an <italic toggle="yes">SDHA</italic> germline pathogenic variant in 3% of individuals with apparently sporadic paragangliomas and pheochromocytomas. The gene <italic toggle="yes">SDHAF2</italic> is a rare cause of hereditary head/neck paraganglioma and is not associated with pheochromocytoma [<xref ref-type="bibr" rid="men2.REF.bayley.2010.366">Bayley et al 2010</xref>].</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">TMEM127</italic> associated susceptibility to pheochromocytoma</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613403">613403</ext-link>). Recent studies estimate that 1%-2% of individuals with familial or nonfamilial pheochromocytoma have a germline <italic toggle="yes">TMEM127</italic> pathogenic variant [<xref ref-type="bibr" rid="men2.REF.yao.2010.2611">Yao et al 2010</xref>, <xref ref-type="bibr" rid="men2.REF.abermil.2012.e805">Abermil et al 2012</xref>]. A few individuals with a germline <italic toggle="yes">TMEM127</italic> pathogenic variant have paragangliomas of the head/neck or at extra-adrenal sites [<xref ref-type="bibr" rid="men2.REF.neumann.2011.e1279">Neumann et al 2011</xref>].</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">MAX</italic> associated susceptibility to pheochromocytoma.</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/154950">154950</ext-link>). A <italic toggle="yes">MAX</italic> germline pathogenic variant is seen in approximately 1% of individuals with familial or nonfamilial pheochromocytoma [<xref ref-type="bibr" rid="men2.REF.burnichon.2012a.5397">Burnichon et al 2012a</xref>]. Pheochromocytomas in individuals with <italic toggle="yes">MAX</italic> pathogenic variants are often bilateral [<xref ref-type="bibr" rid="men2.REF.burnichon.2012b.2828">Burnichon et al 2012b</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Neurofibromatosis type 1.</bold> Pheochromocytomas are observed on occasion in <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">neurofibromatosis type 1</related-object> (NF1). Most individuals with NF1 could be diagnosed based on clinical features including multiple caf&#x000e9;-au-lait macules, neurofibromas, Lisch nodules, axillary or inguinal freckling, and/or positive family history.</p>
          </list-item>
          <list-item>
            <p><bold>Polycythemia and paraganglioma/pheochromocytoma.</bold>
<italic toggle="yes">HIF2A/EPAS1, PHD1, and PHD2</italic> pathogenic variants have been identified in individuals with polycythemia and paraganglioma [<xref ref-type="bibr" rid="men2.REF.lorenzo.2013.507">Lorenzo et al 2013</xref>, <xref ref-type="bibr" rid="men2.REF.ta_eb.2013.e908">Ta&#x000ef;eb et al 2013</xref>, <xref ref-type="bibr" rid="men2.REF.yang.2015.93">Yang et al 2015</xref>].</p>
          </list-item>
        </list>
        <p><related-object link-type="booklink" source-id="gene" document-id="men1" document-type="chapter"><bold>Multiple endocrine neoplasia type 1</bold></related-object>
<bold>(MEN 1).</bold> This endocrinopathy is genetically and clinically distinct from MEN 2; the similar nomenclature for MEN 1 and MEN 2 may cause confusion. MEN 1 is characterized by a triad of pituitary adenomas, pancreatic islet cell tumors, and parathyroid disease consisting of hyperplasia or adenoma. Affected individuals can also have adrenal cortical tumors, carcinoid tumors, and lipomas [<xref ref-type="bibr" rid="men2.REF.giraud.1998.455">Giraud et al 1998</xref>]. MEN 1 is caused by a germline pathogenic variant in <italic toggle="yes">MEN1</italic> and inherited in an autosomal dominant manner.</p>
        <p><bold>Multiple endocrine neoplasia type 4 (MEN 4).</bold> While pheochromocytomas developed in the MENX rat model, humans with pathogenic variants in <italic toggle="yes">CDKN1B</italic> tend to have a phenotype similar to MEN 1 with a high incidence of pituitary tumors and primary hyperparathyroidism [<xref ref-type="bibr" rid="men2.REF.lee.2013.781">Lee &#x00026; Pellegata 2013</xref>].</p>
      </sec>
      <sec id="men2.Management">
        <title>Management</title>
        <sec id="men2.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with multiple endocrine neoplasia type 2 (MEN 2), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Referral to an endocrinologist</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
            <list-item>
              <p>Biochemical evaluations</p>
              <list list-type="bullet">
                <list-item>
                  <p>Plasma calcitonin</p>
                </list-item>
                <list-item>
                  <p>Plasma catecholamines and metanephrines</p>
                </list-item>
                <list-item>
                  <p>Serum calcium and parathyroid hormone</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Workup to evaluate for metastatic disease in individuals with MTC</p>
              <list list-type="bullet">
                <list-item>
                  <p>CT with contrast for chest and abdomen</p>
                </list-item>
                <list-item>
                  <p>MRI of liver with nodal disease or calcitonin &#x0003e;400 pg/mL</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="men2.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Medullary thyroid carcinoma (MTC).</bold> Standard treatment for MTC is surgical removal of the thyroid and lymph node dissection [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>, <xref ref-type="bibr" rid="men2.REF86">National Comprehensive Cancer Network 2015</xref>]. Current NCCN guidelines recommend consideration of therapeutic external beam radiation therapy (EBRT) or intensity-modulated radiation therapy (IMRT) for incomplete tumor resection or extrathyroidal extension with positive margins [<xref ref-type="bibr" rid="men2.REF86">National Comprehensive Cancer Network 2015</xref>]. Two kinase inhibitors &#x02013; vandetanib and cabozantinib &#x02013; have been shown to improve progression-free survival and in some cases cause disease regression in unresectable or advanced metastatic MTC [<xref ref-type="bibr" rid="men2.REF.elisei.2013.3639">Elisei et al 2013</xref>, <xref ref-type="bibr" rid="men2.REF.wells.2013.3149">Wells et al 2013</xref>].</p>
          <p>All individuals who have undergone thyroidectomy need thyroid hormone replacement therapy.</p>
          <p>Autotransplantation of parathyroid tissue is not typically performed at the time of thyroidectomy unless there is evidence of hyperparathyroidism [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          <p><bold>Pheochromocytomas</bold> detected by biochemical testing and radionuclide imaging are removed by adrenalectomy, which may be performed using video-assisted laparoscopy. Historically, some specialists recommended bilateral adrenalectomy at the time of demonstration of tumor on just a single adrenal gland because of the strong probability that the other adrenal gland would develop a tumor within ten years. However, because of the risk for adrenal insufficiency and Addisonian crisis following bilateral adrenalectomy, most experts now recommend unilateral adrenalectomy in unilateral tumors and cortical-sparing adrenal surgery with close monitoring of the remnant tissue in persons with one remaining adrenal gland or bilateral pheochromocytoma [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          <p>Hypertensive treatment prior to adrenalectomy involves the use of &#x003b1;- and &#x003b2;-adrenergic receptor blockade [<xref ref-type="bibr" rid="men2.REF.pacak.2005.60">Pacak et al 2005</xref>].</p>
          <p><bold>Parathyroid adenoma or hyperplasia</bold> diagnosed at the time of thyroidectomy is treated either with resection of the visibly enlarged parathyroid gland(s), subtotal parathyroidectomy, or total parathyroidectomy with forearm autograft [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. However, in most individuals with MEN 2A, hyperparathyroidism is diagnosed many years after thyroidectomy.</p>
          <p>Individuals with biochemical evidence of primary hyperparathyroidism who have undergone prior thyroidectomy should have preoperative localization with excision of the localized hypertrophied parathyroid glands and forearm autotransplantation.</p>
          <p>Therapy with medications to control primary hyperparathyroidism should be considered in individuals with a high risk for surgical mortality, limited life expectancy, or persistent or recurrent primary hyperparathyroidism after one or more surgical attempts [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
        </sec>
        <sec id="men2.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p><bold>Prophylactic thyroidectomy</bold> is the primary preventive measure for individuals with an identified germline <italic toggle="yes">RET</italic> pathogenic variant [<xref ref-type="bibr" rid="men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          <p>Prophylactic thyroidectomy is safe for all age groups; however, the timing of the surgery is controversial [<xref ref-type="bibr" rid="men2.REF.moley.1998.521">Moley et al 1998</xref>]. According to the consensus statement from the American Thyroid Association Guidelines Task Force, the age at which prophylactic thyroidectomy is performed can be guided by the codon position of the <italic toggle="yes">RET</italic> pathogenic variant (<xref ref-type="table" rid="men2.T.risk_for_aggressive_mtc_based_on_1">Table 4</xref>, <xref ref-type="sec" rid="men2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>) [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. However, these guidelines continue to be modified as more data become available.</p>
          <table-wrap id="men2.T.risk_for_aggressive_mtc_based_on_1" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Risk for Aggressive MTC Based on Genotype and Recommended Interventions</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_1">ATA&#x000a0;<sup>1</sup> Risk Level</th>
                  <th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_2">Pathogenic Variants&#x000a0;<sup>2,&#x000a0;3</sup></th>
                  <th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_3">Age of Prophylactic Surgery</th>
                  <th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Age to Begin Screening</th>
                </tr>
                <tr>
                  <th headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4" id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">For PHEO</th>
                  <th headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4" id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">For HPT&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level D<break/>(highest risk)</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala883Phe<break/>p.Met918Thr<break/>p.Val804Met+p.Glu805Lys&#x000a0;<sup>5</sup><break/>p.Val804Met+p.Tyr806Cys&#x000a0;<sup>5</sup><break/>p.Val804Met+p.Ser904Cys&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">As soon as possible in 1st year of life</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">8 yrs</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level C</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys634Arg/Gly/Phe/Ser/Trp/Tyr</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;5 yrs</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">8 yrs</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">8 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level B</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys609Phe/Arg/Gly/Ser/Tyr<break/>p.Cys611Arg/Gly/Phe/Ser/Trp/Tyr<break/>p.Cys618Arg/Gly/Phe/Ser/Tyr<break/>p.Cys620Arg/Gly/Phe/Ser/Trp/Tyr<break/>p.Cys630Arg/Phe/Ser/Tyr<break/>p.Asp631Tyr<break/>p.633/9 bp dup<break/>p.634/12 bp dup<break/>p.Val804Met+p.Val778Ile&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Consider &#x0003c;5 yrs; may delay if criteria met&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Codon 630 pathogenic variant: 8 yrs<break/>All others: 20 yrs</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Codon 630 pathogenic variant: 8 yrs<break/>All others: 20 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Level A</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg321Gly<break/>p.531/9 bp dup<break/>p.532 dup<break/>p.Cys515Ser<break/>p.Gly533Cys<break/>p.Arg600Gln<break/>p.Lys603Glu<break/>p.Tyr606Cys<break/>p.635/insert ELCR;p.Thr636Pro<break/>p.Lys666Glu<break/>p.Glu768Asp<break/>p.Asn777Ser<break/>p.Leu790Phe<break/>p.Val804Leu/Met<break/>p.Gly819Lys<break/>p.Arg833Cys<break/>p.Arg844Gln<break/>p.Arg866Trp<break/>p.Ser891Ala<break/>p.Arg912Pro</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">May delay beyond age 5 yrs if criteria met&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">20 yrs</td>
                  <td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">20 yrs</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Adapted from <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force [2009]</xref></p>
              </fn>
              <fn id="men2.TF.4.1">
                <label>1. </label>
                <p>ATA = American Thyroid Association</p>
              </fn>
              <fn id="men2.TF.4.2">
                <label>2. </label>
                <p>p.Ser649Leu and p.Tyr791Phe have been removed from this list as they were reclassified as benign variants [<xref ref-type="bibr" rid="men2.REF.erlic.2010.308">Erlic et al 2010</xref>].</p>
              </fn>
              <fn id="men2.TF.4.3">
                <label>3. </label>
                <p>Pathogenic variant designations have not been edited by <italic toggle="yes">GeneReviews</italic> staff and may not be standard nomenclature.</p>
              </fn>
              <fn id="men2.TF.4.4">
                <label>4. </label>
                <p>HPT = Hyperparathyroidism</p>
              </fn>
              <fn id="men2.TF.4.5">
                <label>5. </label>
                <p>Pathogenic variants in <italic toggle="yes">cis</italic> configuration on one allele</p>
              </fn>
              <fn id="men2.TF.4.6">
                <label>6. </label>
                <p>Criteria: normal annual basal and or stimulated serum calcitonin; normal annual neck ultrasound examination; family history of less aggressive MTC</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Thyroidectomy for C-cell hyperplasia,</bold> before progression to invasive MTC, may allow surgery to be limited to thyroidectomy with sparing of lymph nodes [<xref ref-type="bibr" rid="men2.REF.brandi.2001.5658">Brandi et al 2001</xref>, <xref ref-type="bibr" rid="men2.REF.kahraman.2003.331">Kahraman et al 2003</xref>].</p>
          <p><bold>For all individuals with a <italic toggle="yes">RET</italic> pathogenic variant who have not had a thyroidectomy</bold>, annual biochemical screening is recommended with immediate thyroidectomy if results are abnormal [<xref ref-type="bibr" rid="men2.REF.szinnai.2003.e132">Szinnai et al 2003</xref>].</p>
          <p><bold>Annual serum calcitonin screening</bold> [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>] should begin at age:</p>
          <list list-type="bullet">
            <list-item>
              <p>Six months for children with MEN 2B</p>
            </list-item>
            <list-item>
              <p>Three to five years for children with MEN 2A or FMTC</p>
            </list-item>
          </list>
          <p>Caution should be used in interpreting calcitonin results for children younger than age three years, especially those younger than age six months [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          <p><bold>Prophylactic thyroidectomy</bold> is not routinely offered to at-risk individuals in whom the disorder has not been confirmed.</p>
        </sec>
        <sec id="men2.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Prior to any surgery, the presence of a functioning pheochromocytoma should be excluded by appropriate biochemical screening in any individual with MEN 2A or MEN 2B. In a prospective study of at-risk family members with the pathogenic variant, 8% had pheochromocytoma detected at the same time as MTC [<xref ref-type="bibr" rid="men2.REF.nguyen.2001.37">Nguyen et al 2001</xref>].</p>
          <p>If pheochromocytoma is detected, adrenalectomy should be performed before thyroidectomy to avoid intraoperative catecholamine crisis [<xref ref-type="bibr" rid="men2.REF.lee.2000.111">Lee &#x00026; Norton 2000</xref>].</p>
        </sec>
        <sec id="men2.Surveillance">
          <title>Surveillance</title>
          <p><bold>MTC.</bold> Approximately 50% of individuals diagnosed with MTC who have undergone total thyroidectomy and neck nodal dissections have recurrent disease [<xref ref-type="bibr" rid="men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</xref>]. Furthermore, thyroid glands removed from individuals with a <italic toggle="yes">RET</italic> pathogenic variant who had normal plasma calcitonin concentrations have been found to contain MTC [<xref ref-type="bibr" rid="men2.REF.skinner.1996.177">Skinner et al 1996</xref>]. Therefore, continued monitoring for residual or recurrent MTC is indicated after thyroidectomy, even if thyroidectomy is performed prior to biochemical evidence of disease.</p>
          <p>The screening protocol for MTC after prophylactic thyroidectomy is an annual measurement of serum calcitonin [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. More frequent follow up is recommended for those with residual disease.</p>
          <p><bold>Hypoparathyroidism.</bold> All individuals who have undergone thyroidectomy and autotransplantation of the parathyroids need monitoring for possible hypoparathyroidism.</p>
          <p><bold>Pheochromocytoma.</bold> For individuals whose initial screening results are negative for pheochromocytoma, annual biochemical screening is recommended, followed by MRI and/or CT if the biochemical results are abnormal [<xref ref-type="bibr" rid="men2.REF.pacak.2005.60">Pacak et al 2005</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. Women with MEN 2 should be screened for pheochromocytoma prior to a planned pregnancy, or as early as possible during an unplanned pregnancy [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>]. Other screening studies, such as scintigraphy or positron emission tomography, may be warranted in some individuals.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>MEN 2A.</bold> Annual biochemical screening beginning at age eight years has been recommended for individuals with a pathogenic variant in codons 630 and 634 and at age 20 years for a pathogenic variant in all other codons [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>FMTC.</bold> Screening as for MEN 2A is indicated, as not all families classified as FMTC are MTC-only [<xref ref-type="bibr" rid="men2.REF.moers.1996.635">Moers et al 1996</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>MEN 2B.</bold> Annual screening should begin at age eight years [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
            </list-item>
          </list>
          <p><bold>Parathyroid adenoma or hyperplasia.</bold> Annual biochemical screening is recommended for affected individuals who have not had parathyroidectomy and parathyroid autotransplantation.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>MEN 2A.</bold> Screening should start at age eight years for individuals with a pathogenic variant in codons 630 and 634, and by age 20 years for individuals with other <italic toggle="yes">RET</italic> pathogenic variants [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>FMTC.</bold> Periodic screening should begin at age 20 years [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>MEN 2B.</bold> Screening is unnecessary as individuals with MEN 2B do not have an increased risk of hyperparathyroidism.</p>
            </list-item>
          </list>
        </sec>
        <sec id="men2.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Dopamine D<sub>2</sub> receptor antagonists (e.g., metoclopramide and veralipride) and &#x003b2;-adrenergic receptor antagonists (&#x003b2;-blockers) have a high potential to cause an adverse reaction in individuals with pheochromocytoma.</p>
          <p>Other medications including monoamine oxidase inhibitors, sympathomimetics (e.g., ephedrine), and certain peptide and corticosteroid hormones may also cause complications; tricyclic antidepressants are inconsistent in causing adverse reactions [<xref ref-type="bibr" rid="men2.REF.eisenhofer.2007.1031">Eisenhofer et al 2007</xref>].</p>
        </sec>
        <sec id="men2.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures. The American Society of Clinical Oncologists (ASCO) identifies MEN 2 as a Group 1 disorder, i.e., a well-defined hereditary cancer syndrome for which genetic testing is considered part of the standard management for at-risk family members [<xref ref-type="bibr" rid="men2.REF1">American Society of Clinical Oncology 2003</xref>]. Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variant in the family is known:</p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>MEN 2A.</bold>
<italic toggle="yes">RET</italic> molecular genetic testing should be offered to at-risk children by age five years. The finding of MTC in the thyroid of a 12-month-old with a <italic toggle="yes">RET</italic> pathogenic variant suggests that molecular genetic testing should be performed even earlier when possible [<xref ref-type="bibr" rid="men2.REF.machens.2004.1083">Machens et al 2004</xref>].</p>
                </list-item>
                <list-item>
                  <p><bold>FMTC.</bold> Recommendations for families with known FMTC are the same as for MEN 2A.</p>
                </list-item>
                <list-item>
                  <p><bold>MEN 2B.</bold>
<italic toggle="yes">RET</italic> molecular genetic testing should be performed as soon as possible after birth in all children known to be at risk [<xref ref-type="bibr" rid="men2.REF.brandi.2001.5658">Brandi et al 2001</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>The following screening of at-risk family members if the pathogenic variant in the family is not known:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Neck ultrasound examination and basal and/or stimulated calcitonin measurements for MTC</p>
                </list-item>
                <list-item>
                  <p>Albumin-corrected calcium or ionized calcium for hyperparathyroidism</p>
                </list-item>
                <list-item>
                  <p>Measurement of plasma or 24-hour urine metanephrines and normetanephrines as appropriate [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>] for pheochromocytoma</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="men2.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="men2.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Women with MEN 2 should be screened for pheochromocytoma prior to a planned pregnancy, or as early as possible during an unplanned pregnancy [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
        </sec>
        <sec id="men2.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Clinical trials of multikinase inhibitors such as sorafenib, sunitinib, and ponatinib are currently underway. NCCN guidelines recommend consideration of clinical trial participation for individuals who fail standard treatment with vandetanib and cabozantinib [<xref ref-type="bibr" rid="men2.REF86">National Comprehensive Cancer Network 2015</xref>].</p>
          <p>Sorafenib is FDA approved for use in renal cell and hepatocellular carcinoma. In a Phase II clinical trial of sorafenib, 16 individuals with sporadic MTC had a partial response (1/16) or stable disease (15/16) [<xref ref-type="bibr" rid="men2.REF.lam.2010.2323">Lam et al 2010</xref>]. A small Phase II trial of treatment with sunitinib demonstrated objective response in three (50%) of six individuals with metastatic MTC and stable disease in two individuals [<xref ref-type="bibr" rid="men2.REF.carr.2010.5260">Carr et al 2010</xref>]. Ponatinib has been shown to inhibit RET kinase activity and diminish medullary thyroid cancer in mice [<xref ref-type="bibr" rid="men2.REF.de_falco.2013.e811">De Falco et al 2013</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="men2.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="men2.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>All of the multiple endocrine neoplasia type 2 (MEN 2) subtypes are inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="men2.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The proportion of individuals with MEN 2 who have an affected parent varies by subtype:</p>
              <list list-type="bullet">
                <list-item>
                  <p>MEN 2A</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>95% of individuals diagnosed with MEN 2A have an affected parent. The penetrance for MTC, pheochromocytoma, and parathyroid disease varies by MEN 2 subtype (see <xref ref-type="table" rid="men2.T.percent_of_clinical_features_by_m">Table 2</xref>).</p>
                    </list-item>
                    <list-item>
                      <p>A proband with MEN 2A may have the disorder as the result of a <italic toggle="yes">de novo</italic> germline <italic toggle="yes">RET</italic> pathogenic variant. The proportion of cases caused by a <italic toggle="yes">de novo</italic> germline pathogenic variant is approximately 5% [<xref ref-type="bibr" rid="men2.REF.schuffenecker.1997.233">Schuffenecker et al 1997</xref>].</p>
                    </list-item>
                    <list-item>
                      <p>It is appropriate to evaluate the parents of an individual with MEN 2A for manifestations of the disorder and offer molecular genetic testing if the <italic toggle="yes">RET</italic> pathogenic variant has been identified in the proband (see Diagnosis, <xref ref-type="sec" rid="men2.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>).</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p><bold>FMTC.</bold> By definition, individuals with FMTC have multiple family members who are affected.</p>
                </list-item>
                <list-item>
                  <p>
                    <bold>MEN 2B</bold>
                  </p>
                  <list list-type="bullet">
                    <list-item>
                      <p>50% of individuals diagnosed with MEN 2B have an affected parent. The penetrance for MTC, pheochromocytoma, and parathyroid disease varies by MEN 2 subtype (see <xref ref-type="table" rid="men2.T.percent_of_clinical_features_by_m">Table 2</xref>).</p>
                    </list-item>
                    <list-item>
                      <p>A proband with MEN 2B may have the disorder as the result of a <italic toggle="yes">de novo</italic> germline <italic toggle="yes">RET</italic> pathogenic variant [<xref ref-type="bibr" rid="men2.REF.carlson.1994.1076">Carlson et al 1994</xref>].</p>
                      <p>The proportion of MEN 2B caused by a <italic toggle="yes">de novo</italic> germline <italic toggle="yes">RET</italic> pathogenic variant is 50%.</p>
                      <p>The majority of <italic toggle="yes">de novo</italic> pathogenic variants are paternal in origin, but maternal origin has been reported.</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> germline pathogenic variant in the proband. Although no instances of germline mosaicism have been reported in MEN 2, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with a clinical diagnosis of MEN 2 and an undetectable <italic toggle="yes">RET</italic> pathogenic variant include thyroid ultrasound and biochemical screening for MTC, pheochromocytoma, and hyperparathyroidism.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with MEN 2 may appear to be negative because of failure to recognize the disorder in family members, reduced penetrance, early death of the parent before the onset of symptoms, or late onset of the disorder in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or molecular genetic testing has been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband has the germline <italic toggle="yes">RET</italic> pathogenic variant, the risk to the sibs of inheriting the variant is 50%.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for MEN 2 because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">RET</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism; germline mosaicism has not yet been reported.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with MEN 2 has a 50% chance of inheriting the <italic toggle="yes">RET</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The probability that the offspring of an individual with simplex medullary thyroid carcinoma (MTC) (i.e., no known family history of MTC) and no identifiable <italic toggle="yes">RET</italic> germline pathogenic variant would inherit a <italic toggle="yes">RET</italic> pathogenic variant is 0.18% [<xref ref-type="bibr" rid="men2.REF.brandi.2001.5658">Brandi et al 2001</xref>, <xref ref-type="bibr" rid="men2.REF.massoll.2004.49">Massoll &#x00026; Mazzaferri 2004</xref>]. This is based on a 95% pathogenic variant detection rate and on empiric data that 7% of individuals with sporadic MTC have a germline <italic toggle="yes">RET</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent has a germline <italic toggle="yes">RET</italic> pathogenic variant, his or her family members are at increased risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="men2.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="men2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Testing of at-risk individuals.</bold> Consideration of molecular genetic testing of at-risk family members is appropriate for surveillance (see <xref ref-type="sec" rid="men2.Surveillance">Surveillance</xref>). Molecular genetic testing (see <xref ref-type="sec" rid="men2.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>) can be used for testing of at-risk relatives only if a germline pathogenic variant has been identified in the family. When a known pathogenic variant is not identified, linkage analysis (see <xref ref-type="sec" rid="men2.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>) can be considered in families with more than one affected family member from different generations. Because early detection of at-risk individuals affects medical management, testing of asymptomatic children is beneficial [<xref ref-type="bibr" rid="men2.REF1">American Society of Clinical Oncology 2003</xref>]. Education and genetic counseling of at-risk children and their parents prior to genetic testing are appropriate.</p>
          <p><bold>Genetic cancer risk assessment and counseling.</bold> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without molecular genetic testing, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</ext-link> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with MEN 2 has the pathogenic variant or clinical evidence of the disorder, the <italic toggle="yes">RET</italic> pathogenic variant is likely <italic toggle="yes">de novo</italic>, or germline mosaicism exists. However, other possible non-medical explanations that could also be explored include alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="men2.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">RET</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for MEN 2 are possible [<xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="men2.Resources">
        <title>Resources</title>
      </sec>
      <sec id="men2.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The <italic toggle="yes">RET</italic> proto-oncogene comprises 21 exons over 55 kb of genomic sequence. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="men2" object-id="men2.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants.</bold> Benign variants as well as variants of uncertain significance have been described. See <related-object source-id="gene" document-id="men2" object-id="men2.molgen.TA">Table A</related-object>, <bold>Locus Specific</bold> for a database of normal, uncertain, and pathogenic <italic toggle="yes">RET</italic> variants [<xref ref-type="bibr" rid="men2.REF.margraf.2009.548">Margraf et al 2009</xref>].</p>
        <p>It is speculated that some rare variants (e.g., p.Val648Ile) may modify the phenotype when inherited with a pathogenic variant [<xref ref-type="bibr" rid="men2.REF.nunes.2002.5658">Nunes et al 2002</xref>].</p>
        <p>Evidence suggests that other rare allelic variants may be predisposition factors. For example, p.Gly691Ser and p.Ser904Ser may be low-penetrance risk factors for development of medullary thyroid carcinoma (MTC) [<xref ref-type="bibr" rid="men2.REF.robledo.2003.1814">Robledo et al 2003</xref>, <xref ref-type="bibr" rid="men2.REF.elisei.2004.3579">Elisei et al 2004</xref>] and may predispose individuals with a pathogenic variant to an earlier age of onset of MEN 2A [<xref ref-type="bibr" rid="men2.REF.gil.2002.299">Gil et al 2002</xref>, <xref ref-type="bibr" rid="men2.REF.robledo.2003.1814">Robledo et al 2003</xref>, <xref ref-type="bibr" rid="men2.REF.cardotbauters.2008.506">Cardot-Bauters et al 2008</xref>]; however, this finding was not replicated in a larger study [<xref ref-type="bibr" rid="men2.REF.lesueur.2006.1177">Lesueur et al 2006</xref>]. The p.Ser836Ser variant has been associated with an increased risk for nonfamilial MTC in at least two studies [<xref ref-type="bibr" rid="men2.REF.gimm.1999.1369">Gimm et al 1999</xref>, <xref ref-type="bibr" rid="men2.REF.ruiz.2001.399">Ruiz et al 2001</xref>] but not in another [<xref ref-type="bibr" rid="men2.REF.berard.2004.150">Berard et al 2004</xref>]. A meta-analysis of six allelic variants found a modest nonfamilial MTC association with p.Ser836Ser and a strong association with the promoter benign variant IVS1-126G&#x0003e;T [<xref ref-type="bibr" rid="men2.REF.figlioli.2013.36">Figlioli et al 2013</xref>].</p>
        <p>Although the variants p.Ser649Leu and p.Tyr791Phe were recently reclassified as non-pathogenic, it is unknown if they act as modifiers of risk [<xref ref-type="bibr" rid="men2.REF.erlic.2010.308">Erlic et al 2010</xref>].</p>
        <p>At this time, there is insufficient data from association studies to direct individual patient care.</p>
        <p><bold>Pathogenic variants.</bold> The major pathogenic variants are non-conservative substitutions located in one of six cysteine codons in the extracellular domain of the encoded protein. They include codons 609, 611, 618, and 620 in exon 10 and codons 630 and 634 in exon 11 [<xref ref-type="bibr" rid="men2.REF.takahashi.1998.509">Takahashi et al 1998</xref>]. All of these variants have been identified in families with MEN 2A and some have been identified in families with FMTC. Pathogenic variants in these sites have been detected in 98% of families with MEN 2A [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>]. See <related-object source-id="gene" document-id="men2" object-id="men2.molgen.TA">Table A</related-object> for a database of <italic toggle="yes">RET</italic> variants [<xref ref-type="bibr" rid="men2.REF.margraf.2009.548">Margraf et al 2009</xref>].</p>
        <p>The risk of aggressive MTC, pheochromocytoma, and hyperparathyroidism can be estimated based on genotype. See <xref ref-type="table" rid="men2.T.risk_for_aggressive_mtc_based_on_1">Table 4</xref> for management recommendations.</p>
        <p>Approximately 95% of all individuals with the MEN 2B phenotype have a single nucleotide variant (SNV) in the tyrosine kinase domain of <italic toggle="yes">RET</italic> at codon 918 in exon 16, which substitutes a threonine for methionine [<xref ref-type="bibr" rid="men2.REF.eng.1996.1575">Eng et al 1996</xref>]. A second SNV at codon 883 has been found in 2%-3% of individuals with MEN 2B [<xref ref-type="bibr" rid="men2.REF.gimm.1997.3902">Gimm et al 1997</xref>, <xref ref-type="bibr" rid="men2.REF.smith.1997.1213">Smith et al 1997</xref>]. Tandem <italic toggle="yes">RET</italic> pathogenic variants in codons 805, 806, and 904 in <italic toggle="yes">cis</italic> configuration with the p.Val804Met pathogenic variant have also been reported in individuals with MEN 2B [<xref ref-type="bibr" rid="men2.REF.miyauchi.1999.1">Miyauchi et al 1999</xref>, <xref ref-type="bibr" rid="men2.REF.menko.2002.393">Menko et al 2002</xref>, <xref ref-type="bibr" rid="men2.REF.cranston.2006.10179">Cranston et al 2006</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
        <p>In addition to the pathogenic variants in the cysteine residues in exons 10 and 11 that have been found in families with MEN 2A, pathogenic variants in codons 631, 768, 790, 804, 844, and 891, and others in exons 5, 8, 10, 11, and 13 to 16 have been identified in a small number of families [<xref ref-type="bibr" rid="men2.REF.hofstra.1997.4176">Hofstra et al 1997</xref>, <xref ref-type="bibr" rid="men2.REF.berndt.1998.770">Berndt et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">American Thyroid Association Guidelines Task Force 2009</xref>].</p>
        <p>A pathogenic variant at codon 603 was reported in one family and appeared to be associated with both MTC and papillary thyroid cancer [<xref ref-type="bibr" rid="men2.REF.rey.2001.390">Rey et al 2001</xref>]. The pathogenic variant p.Arg912Pro appeared to be associated with FMTC in two families [<xref ref-type="bibr" rid="men2.REF.jimenez.2004b.4142">Jimenez et al 2004b</xref>].</p>
        <p>Small, in-frame duplications have been reported in four families [<xref ref-type="bibr" rid="men2.REF.h_ppner.1997.587">H&#x000f6;ppner &#x00026; Ritter 1997</xref>, <xref ref-type="bibr" rid="men2.REF.h_ppner.1998.s128">H&#x000f6;ppner et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.pigny.1999.1700">Pigny et al 1999</xref>, <xref ref-type="bibr" rid="men2.REF.niccolisire.2003.1029">Niccoli-Sire et al 2003</xref>].</p>
        <p>Rare families with two pathogenic variants in <italic toggle="yes">cis</italic> configuration have been reported; for example, alteration of both codons 634 and 635 in one family with MEN 2A; alteration of both codons 804 and 844 in one family with FMTC [<xref ref-type="bibr" rid="men2.REF.bartsch.2000.128">Bartsch et al 2000</xref>]; and alteration of codons 804 and 806 in an individual with MEN 2B [<xref ref-type="bibr" rid="men2.REF.miyauchi.1999.1">Miyauchi et al 1999</xref>].</p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">RET</italic> produces a receptor tyrosine kinase with extracellular, transmembrane, and intracellular domains. The extracellular domain consists of a calcium-binding cadherin-like region and a cysteine-rich region. The encoded protein plays a role in signal transduction by interaction with the glial-derived neurotropic factor (GDNF) family of ligands: GDNF, neurturin, persephin, and artemin. Ligand interaction is via the ligand-binding GDNF family receptors (GFR&#x003b1;) to which RET protein binds the encoded protein complexes. Formation of a complex containing two RET protein molecules leads to RET autophosphorylation and intracellular signaling whereby phosphorylated tyrosines become docking sites for intracellular signaling proteins [<xref ref-type="bibr" rid="men2.REF.santoro.2004.5448">Santoro et al 2004</xref>]. The RET tyrosine kinase catalytic core, which is located in the intracellular domain, interacts with the docking protein FRS2 and causes downstream activation of the mitogen-activated protein (MAP) kinase signaling cascade [<xref ref-type="bibr" rid="men2.REF.mani_.2001.580">Mani&#x000e9; et al 2001</xref>]. Normal tissues contain transcripts of several lengths [<xref ref-type="bibr" rid="men2.REF.takaya.1996.617">Takaya et al 1996</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants in codons in the cysteine-rich extracellular domain (609, 611, 618, 620, and 634) cause ligand-independent RET dimerization, leading to constitutive activation (i.e., gain of function) of tyrosine kinase [<xref ref-type="bibr" rid="men2.REF.takahashi.1998.509">Takahashi et al 1998</xref>].</p>
        <p>The pathogenic variant in codon 918 that causes 95% of the MEN 2B phenotype lies within the catalytic core of the tyrosine kinase and causes a constitutive activation (i.e., gain of function) of the RET kinase in its monomeric state, independent of the normal ligand-binding and dimerization steps [<xref ref-type="bibr" rid="men2.REF.takahashi.1998.509">Takahashi et al 1998</xref>].</p>
        <p>In contrast to the activating pathogenic variants in MEN 2, pathogenic variants that cause <related-object link-type="booklink" source-id="gene" document-id="hirschsprung-ov" document-type="chapter">Hirschsprung disease</related-object> (HSCR) result in a decrease in the transforming activity of RET [<xref ref-type="bibr" rid="men2.REF.iwashita.1996.1577">Iwashita et al 1996</xref>]. For families in which MEN 2A and HSCR cosegregate, models to explain how the same pathogenic variant can cause gain of function and loss of function have been proposed [<xref ref-type="bibr" rid="men2.REF.takahashi.1999.331">Takahashi et al 1999</xref>].</p>
        <sec id="men2.Cancer_and_Benign_Tumors">
          <title>Cancer and Benign Tumors</title>
          <p><bold>Fusion proteins.</bold> Approximately 20%-40% of papillary thyroid carcinoma is associated with somatic gene rearrangements that cause juxtaposition of the tyrosine kinase domain of <italic toggle="yes">RET</italic> to various gene partners [<xref ref-type="bibr" rid="men2.REF.tallini.1998.287">Tallini et al 1998</xref>, <xref ref-type="bibr" rid="men2.REF.santoro.2002.370">Santoro et al 2002</xref>, <xref ref-type="bibr" rid="men2.REF.puxeddu.2003.505">Puxeddu et al 2003</xref>].</p>
        </sec>
      </sec>
      <sec id="men2.References">
        <title>References</title>
        <sec id="men2.Published_GuidelinesConsensus_State">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="men2.Published_GuidelinesConsensus_State.reflist0">
            <ref id="men2.REF1">
              <mixed-citation publication-type="web">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jco.ascopubs.org/content/21/12/2397.full">online</ext-link>. 2003. Accessed 6-21-17.</mixed-citation>
            </ref>
            <ref id="men2.REF2">
              <mixed-citation publication-type="web">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jco.ascopubs.org/content/28/5/893.long">online</ext-link>; registration or institutional access required. 2010. Accessed 6-21-17</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="men2.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="men2.Literature_Cited.reflist0">
            <ref id="men2.REF.abermil.2012.e805">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abermil</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guillaud-Bataille</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venisse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manivet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guignat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drui</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chupin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Josseaume</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Affres</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plouin</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeunema&#x000ee;tre</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <article-title>TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2012</year>
                <volume>97</volume>
                <fpage>E805</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22419703</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.aiello.2005.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aiello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cioni</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobbo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gullo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Torre</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passerini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrando</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilotti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierotti</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasini</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>The familial medullary thyroid carcinoma-associated RET E768D mutation in a multiple endocrine neoplasia type 2A case.</article-title>
                <source>Surgery.</source>
                <year>2005</year>
                <volume>137</volume>
                <fpage>574</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15855933</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.american_society_of_clinical_oncology.2003.2397">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>American Society of Clinical Oncology</collab>
                </person-group>
                <article-title>American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.</article-title>
                <source>J Clin Oncol.</source>
                <year>2003</year>
                <volume>21</volume>
                <fpage>2397</fpage>
                <lpage>406</lpage>
                <pub-id pub-id-type="pmid">12692171</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.american_thyroid_association_guidelines_task_force.2009.565">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>American Thyroid Association Guidelines Task Force</collab>
                </person-group>
                <article-title>Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association.</article-title>
                <source>Thyroid.</source>
                <year>2009</year>
                <volume>19</volume>
                <fpage>565</fpage>
                <lpage>612</lpage>
                <pub-id pub-id-type="pmid">19469690</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.bartsch.2000.128">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bartsch</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasse</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schug</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rothmund</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;ppner</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>A RET double mutation in the germline of a kindred with FMTC.</article-title>
                <source>Exp Clin Endocrinol Diabetes.</source>
                <year>2000</year>
                <volume>108</volume>
                <fpage>128</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">10826520</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.bayley.2010.366">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bayley</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunst</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sampietro</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korpershoek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinojar-Gutierrez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmers</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoefsloot</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Su&#x000e1;rez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussain</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vriends</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hes</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tops</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corssmit</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Knijff</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenders</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devilee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dinjens</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Krijger</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma.</article-title>
                <source>Lancet Oncol.</source>
                <year>2010</year>
                <volume>11</volume>
                <fpage>366</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">20071235</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.berard.2004.150">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berard</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraimps</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savagner</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renaudin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolli-Sire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertrand</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moisan</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezieau</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population.</article-title>
                <source>Clin Genet.</source>
                <year>2004</year>
                <volume>65</volume>
                <fpage>150</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">14984475</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.berndt.1998.770">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berndt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuter</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saller</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank-Raue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grussendorf</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritter</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;ppner</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>1998</year>
                <volume>83</volume>
                <fpage>770</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9506724</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.boedeker.2009.1938">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boedeker</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erlic</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kontny</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Campos</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Nederveen</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Krijger</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reschke</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiech</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000fc;ckauer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plouin</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darrouzet</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <article-title>Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2009</year>
                <volume>94</volume>
                <fpage>1938</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">19336503</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.brandi.2001.5658">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brandi</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angeli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilezikian</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte-Devolx</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falchetti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gheri</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Libroia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lips</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lombardi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponder</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skogseid</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamburrano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thakker</surname>
                    <given-names>RV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomassetti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>SA</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Marx</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <article-title>Guidelines for diagnosis and therapy of MEN type 1 and type 2.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2001</year>
                <volume>86</volume>
                <fpage>5658</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">11739416</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.brauckhoff.2002.557">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brauckhoff</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinze</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ukkat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brauckhoff</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation.</article-title>
                <source>Thyroid.</source>
                <year>2002</year>
                <volume>12</volume>
                <fpage>557</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">12193298</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.brenner.2008.1117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brenner</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacene</surname>
                    <given-names>HA</given-names>
                  </name>
                </person-group>
                <article-title>Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy.</article-title>
                <source>Otolaryngol Clin North Am.</source>
                <year>2008</year>
                <volume>41</volume>
                <fpage>1117</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">19040973</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.bryant.2003.1196">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farmer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessler</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Townsend</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nathanson</surname>
                    <given-names>KL</given-names>
                  </name>
                </person-group>
                <article-title>Pheochromocytoma: the expanding genetic differential diagnosis.</article-title>
                <source>J Natl Cancer Inst.</source>
                <year>2003</year>
                <volume>95</volume>
                <fpage>1196</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">12928344</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.burnichon.2010.3011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bri&#x000e8;re</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lib&#x000e9;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vescovo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivi&#x000e8;re</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tissier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouanno</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeunemaitre</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;nit</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzagoloff</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rustin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Favier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <article-title>SDHA is a tumor suppressor gene causing paraganglioma.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2010</year>
                <volume>19</volume>
                <fpage>3011</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">20484225</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.burnichon.2012a.5397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buffet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parfait</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letouz&#x000e9;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laurendeau</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loriot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasmant</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abermil</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valeyrie-Allanore</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amar</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidaud</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Favier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <article-title>Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2012a</year>
                <volume>21</volume>
                <fpage>5397</fpage>
                <lpage>405</lpage>
                <pub-id pub-id-type="pmid">22962301</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.burnichon.2012b.2828">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casc&#x000f3;n</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiavi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comino-M&#x000e9;ndez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abermil</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inglada-P&#x000e9;rez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cubas</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amar</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barontini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Quir&#x000f3;s</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bignon</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blok</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bobisse</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borrego</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiara</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corssmit</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giacch&#x000e8;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Krijger</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ercolino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girerd</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Garc&#x000ed;a</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Gra&#x000f1;a</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guilhem</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hes</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honrado</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korpershoek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenders</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Let&#x000f3;n</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mensenkamp</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mori</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plouin</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prodanov</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quesada-Charneco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapizzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncador</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz-Ferrer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schillo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stegmann</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suarez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taschin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmers</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tops</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urioste</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beuschlein</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eisenhofer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.</article-title>
                <source>Clin Cancer Res.</source>
                <year>2012b</year>
                <volume>18</volume>
                <fpage>2828</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">22452945</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.burnichon.2009.2817">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohmer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amar</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leboulleux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darrouzet</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niccoli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaillard</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabolle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coupier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thieblot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecomte</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wion-Barbot</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venisse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plouin</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeunemaitre</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <article-title>PGL.NET network. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2009</year>
                <volume>94</volume>
                <fpage>2817</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">19454582</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.callender.2008.863">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Callender</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rich</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrier</surname>
                    <given-names>ND</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia syndromes.</article-title>
                <source>Surg Clin North Am.</source>
                <year>2008</year>
                <volume>88</volume>
                <fpage>863</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">18672144</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.cardotbauters.2008.506">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cardot-Bauters</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leteurtre</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leclerc</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vantyghem</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Do Cao</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wemeau</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Herbomez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carnaille</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pigny</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Groupe d'Etude des Tumeurs Endocrines (GTE). Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2008</year>
                <volume>69</volume>
                <fpage>506</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">18331611</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.carlson.1994.1076">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carlson</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bracamontes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>SA</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Goodfellow</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Parent-of-origin effects in multiple endocrine neoplasia type 2B.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1994</year>
                <volume>55</volume>
                <fpage>1076</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">7977365</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.carr.2010.5260">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carr</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mankoff</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulart</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eaton</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capell</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kell</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauman</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.</article-title>
                <source>Clin Cancer Res.</source>
                <year>2010</year>
                <volume>16</volume>
                <fpage>5260</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20847059</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.cohen.2003.616">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moley</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <article-title>Surgical treatment of medullary thyroid carcinoma.</article-title>
                <source>J Intern Med.</source>
                <year>2003</year>
                <volume>253</volume>
                <fpage>616</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">12755957</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.cominom_ndez.2011.663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Comino-M&#x000e9;ndez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gracia-Azn&#x000e1;rez</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiavi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landa</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leandro-Garc&#x000ed;a</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Let&#x000f3;n</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honrado</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos-Medina</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caronia</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pita</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Gra&#x000f1;a</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cubas</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inglada-P&#x000e9;rez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maliszewska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taschin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bobisse</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pica</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hern&#x000e1;ndez-Lavado</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000ed;az</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Morales</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonz&#x000e1;lez-Neira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncador</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez-Antona</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben&#x000ed;tez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casc&#x000f3;n</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.</article-title>
                <source>Nat Genet.</source>
                <year>2011</year>
                <volume>43</volume>
                <fpage>663</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21685915</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.costante.2009.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Costante</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durante</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francis</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlumberger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filetti</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.</article-title>
                <source>Nat Clin Pract Endocrinol Metab.</source>
                <year>2009</year>
                <volume>5</volume>
                <fpage>35</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">19079272</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.costante.2007.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Costante</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meringolo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durante</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nocera</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tumino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crocetti</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maranghi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torlontano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filetti</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>450</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17119000</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.cranston.2006.10179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cranston</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carniti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oakhill</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radzio-Andzelm</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCallion</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodgson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mondellini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leyland</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierotti</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittaker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bongarzone</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponder</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.</article-title>
                <source>Cancer Res.</source>
                <year>2006</year>
                <volume>66</volume>
                <fpage>10179</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">17047083</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.de_falco.2013.e811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Falco</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buonocore</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muthu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torregrossa</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basolo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Billaud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gozgit</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlomagno</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2013</year>
                <volume>98</volume>
                <fpage>E811</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23526464</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.de_groot.2006.535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Groot</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Links</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plukker</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lips</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofstra</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <article-title>RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.</article-title>
                <source>Endocr Rev.</source>
                <year>2006</year>
                <volume>27</volume>
                <fpage>535</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">16849421</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.decker.1998.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Decker</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peacock</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1998</year>
                <volume>7</volume>
                <fpage>129</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">9384613</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.delellis.2004">
              <mixed-citation publication-type="book">DeLellis RA, Lloyd RV, Heitz PU, Eng C. <italic toggle="yes">Pathology and Genetics: Tumours of the Endocrine Organs. World Health Organization Classification of Tumours Series.</italic> Vol 8. Lyon, France: IARC Press; 2004.</mixed-citation>
            </ref>
            <ref id="men2.REF.dvorakova.2008.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dvorakova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaclavikova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sykorova</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vcelak</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novak</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duskova</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laco</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cap</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kodetova</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kodet</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krskova</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlcek</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vesely</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bendlova</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.</article-title>
                <source>Mol Cell Endocrinol.</source>
                <year>2008</year>
                <volume>284</volume>
                <fpage>21</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18282654</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.eisenhofer.2007.1031">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eisenhofer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivers</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosas</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quezado</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manger</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.</article-title>
                <source>Drug Saf.</source>
                <year>2007</year>
                <volume>30</volume>
                <fpage>1031</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">17973541</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.elisei.2008.682">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elisei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosci</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bottici</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molinaro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agate</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vivaldi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faviana</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basolo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miccoli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinchera</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2008</year>
                <volume>93</volume>
                <fpage>682</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18073307</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.elisei.2004.3579">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elisei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosci</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bottici</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sculli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lari</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barale</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinchera</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004</year>
                <volume>89</volume>
                <fpage>3579</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">15240649</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.elisei.2007.4725">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elisei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosci</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agate</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bottici</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molinaro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sculli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miccoli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basolo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grasso</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinchera</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>4725</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17895320</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.elisei.2013.3639">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elisei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlumberger</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000f6;ffski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brose</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licitra</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarzab</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medvedev</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kreissl</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederle</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wirth</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ali</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hessel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaron</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelkin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SI</given-names>
                  </name>
                </person-group>
                <article-title>Cabozantinib in progressive medullary thyroid cancer.</article-title>
                <source>J Clin Oncol.</source>
                <year>2013</year>
                <volume>31</volume>
                <fpage>3639</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">24002501</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.eng.1996.1575">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuffenecker</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Amstel</surname>
                    <given-names>HK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lips</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishisho</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takai</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank-Raue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noll</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederle</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zedenius</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordenskj&#x000f6;ld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komminoth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendy</surname>
                    <given-names>GN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulligan</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <article-title>The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.</article-title>
                <source>JAMA</source>
                <year>1996</year>
                <volume>276</volume>
                <fpage>1575</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8918855</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.erlic.2010.308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erlic</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franke</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peczkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harsch</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schott</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabbert</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valim&#x000e4;ki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preuss</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasse-Lazar</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waligorski</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januszewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <article-title>Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2010</year>
                <volume>95</volume>
                <fpage>308</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">19906784</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.erlic.2009.6378">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erlic</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peczkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golcher</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kann</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brauckhoff</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ssig</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muresan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000e4;ffler</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schott</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fassnacht</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klose</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fottner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forrer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pl&#x000f6;ckinger</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersenn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabolotny</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kollukch</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaremchuk</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januszewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walz</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                  <collab>European-American Pheochromocytoma Study Group</collab>
                </person-group>
                <article-title>Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.</article-title>
                <source>Clin Cancer Res.</source>
                <year>2009</year>
                <volume>15</volume>
                <fpage>6378</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">19825962</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.feldman.2000.93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feldman</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edmonds</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ainsworth</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuffenecker</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saxe</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talpos</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucelli</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <article-title>Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG--&#x0003e;ATG) mutation.</article-title>
                <source>Surgery.</source>
                <year>2000</year>
                <volume>128</volume>
                <fpage>93</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10876191</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.figlioli.2013.36">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Figlioli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elisei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gemignani</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.</article-title>
                <source>Mutat Res.</source>
                <year>2013</year>
                <volume>752</volume>
                <fpage>36</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">23059849</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.fishbein.2013.1444">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fishbein</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merrill</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraker</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nathanson</surname>
                    <given-names>KL</given-names>
                  </name>
                </person-group>
                <article-title>Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing.</article-title>
                <source>Ann Surg Oncol.</source>
                <year>2013</year>
                <volume>20</volume>
                <fpage>1444</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">23512077</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.frohnauer.2000.1052">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frohnauer</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decker</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?</article-title>
                <source>Surgery.</source>
                <year>2000</year>
                <volume>128</volume>
                <fpage>1052</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11114642</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.gibelin.2004.1458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gibelin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezieau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misso</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouin-Pineau</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mar&#x000e9;chaud</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraimps</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Germline RET V804M mutation associated with multiple endocrine neoplasia type 2A.</article-title>
                <source>Br J Surg.</source>
                <year>2004</year>
                <volume>91</volume>
                <fpage>1458</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15386323</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.gil.2002.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gil</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aza&#x000f1;edo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll&#x000e1;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cristobal</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arribas</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Albert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-S&#x000e1;iz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maestro</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Men&#x000e1;rguez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rojas</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A.</article-title>
                <source>Int J Cancer.</source>
                <year>2002</year>
                <volume>99</volume>
                <fpage>299</fpage>
                <lpage>304</lpage>
                <pub-id pub-id-type="pmid">11979448</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.gimm.1997.3902">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrew</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frilling</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulligan</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zajac</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>1997</year>
                <volume>82</volume>
                <fpage>3902</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9360560</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.gimm.1999.1369">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuberg</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoang-Vu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinze</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation.</article-title>
                <source>Oncogene.</source>
                <year>1999</year>
                <volume>18</volume>
                <fpage>1369</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">10022819</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.giraud.1998.455">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>CX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serova-Sinilnikova</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wautot</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salandre</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buisson</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterlot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauters</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porchet</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubert</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cadiot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delemer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niccoli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leprat</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duron</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emperauger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cougard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarfati</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riou</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guichard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyrier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vantyghem</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assayag</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peix</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pugeat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohmer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallotton</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudray</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proye</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte-Devolx</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shugart</surname>
                    <given-names>YY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldgar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1998</year>
                <volume>63</volume>
                <fpage>455</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">9683585</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.hansford.2000.817">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hansford</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulligan</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.</article-title>
                <source>J Med Genet.</source>
                <year>2000</year>
                <volume>37</volume>
                <fpage>817</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">11073534</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.hofstra.1997.4176">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hofstra</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fattoruso</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quadro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Libroia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verga</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colantuoni</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buys</surname>
                    <given-names>CH</given-names>
                  </name>
                </person-group>
                <article-title>A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>1997</year>
                <volume>82</volume>
                <fpage>4176</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9398735</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.h_ie.2000.3249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000f8;ie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heimdal</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesland</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f8;rmer</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers.</article-title>
                <source>Tidsskr Nor Laegeforen.</source>
                <year>2000</year>
                <volume>120</volume>
                <fpage>3249</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">11187163</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.h_ppner.1998.s128">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000f6;ppner</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brabant</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A.</article-title>
                <source>Hum Mutat.</source>
                <year>1998</year>
                <supplement>Suppl 1</supplement>
                <fpage>S128</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9452064</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.h_ppner.1997.587">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000f6;ppner</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritter</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1997</year>
                <volume>6</volume>
                <fpage>587</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">9097963</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.ilias.2008.1613">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ilias</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrasquillo</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whatley</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ling</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laz&#x000fa;rov&#x000e1;</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perera</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.</article-title>
                <source>J Nucl Med.</source>
                <year>2008</year>
                <volume>49</volume>
                <fpage>1613</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18794260</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.ilias.2009.89">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ilias</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome.</article-title>
                <source>Endocr Regul.</source>
                <year>2009</year>
                <volume>43</volume>
                <fpage>89</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">19856714</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.inabnet.2000.1007">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inabnet</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caragliano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pertsemlidis</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Pheochromocytoma: inherited associations, bilaterality, and cortex preservation.</article-title>
                <source>Surgery.</source>
                <year>2000</year>
                <volume>128</volume>
                <fpage>1007</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">11114636</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.inoue.1999.1552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimotake</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokiwa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwai</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.</article-title>
                <source>J Pediatr Surg.</source>
                <year>1999</year>
                <volume>34</volume>
                <fpage>1552</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10549772</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.iwashita.1996.1577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iwashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asai</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1996</year>
                <volume>5</volume>
                <fpage>1577</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">8894691</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.jimenez.2004a.3521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jimenez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dang</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schultz</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Naggar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnes</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vassilopoulou-Sellin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoff</surname>
                    <given-names>AO</given-names>
                  </name>
                </person-group>
                <article-title>A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004a</year>
                <volume>89</volume>
                <fpage>3521</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15240641</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.jimenez.2004b.4142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jimenez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habra</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Naggar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                </person-group>
                <article-title>Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004b</year>
                <volume>89</volume>
                <fpage>4142</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15292360</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.kahraman.2003.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kahraman</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Groot</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouwe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofstra</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Links</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijmons</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plukker</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a.</article-title>
                <source>Eur J Surg Oncol.</source>
                <year>2003</year>
                <volume>29</volume>
                <fpage>331</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12711285</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.korpershoek.2011.e1472">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korpershoek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Favier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Gessel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oudijk</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badoual</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gadessaud</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venisse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayley</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dooren</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Herder</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tissier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plouin</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Nederveen</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dinjens</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Krijger</surname>
                    <given-names>RR</given-names>
                  </name>
                </person-group>
                <article-title>SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>E1472</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21752896</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.kouvaraki.2005.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kouvaraki</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrier</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoff</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <article-title>RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.</article-title>
                <source>Thyroid.</source>
                <year>2005</year>
                <volume>15</volume>
                <fpage>531</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">16029119</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.lam.2010.2323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ringel</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kloos</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knopp</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sammet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakely</surname>
                    <given-names>PE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Vasko</surname>
                    <given-names>VV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saji</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snyder</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arbogast</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collamore</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moley</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villalona-Calero</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <article-title>Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.</article-title>
                <source>J Clin Oncol.</source>
                <year>2010</year>
                <volume>28</volume>
                <fpage>2323</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">20368568</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.lecube.2002.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lecube</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oriola</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galard</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e9;mar</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mesa</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sim&#x000f3;</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers.</article-title>
                <source>Surgery.</source>
                <year>2002</year>
                <volume>131</volume>
                <fpage>509</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">12019403</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.lee.2013.781">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellegata</surname>
                    <given-names>NS</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia syndromes associated with mutation of p27.</article-title>
                <source>J Endocrinol Invest.</source>
                <year>2013</year>
                <volume>36</volume>
                <fpage>781</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23800691</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.lee.2000.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norton</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2B--genetic basis and clinical expression.</article-title>
                <source>Surg Oncol.</source>
                <year>2000</year>
                <volume>9</volume>
                <fpage>111</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11356339</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.lesueur.2006.1177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lesueur</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cebrian</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niccoli-Sire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Svensson</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leyland</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittaker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pharoah</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponder</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A.</article-title>
                <source>Cancer Res.</source>
                <year>2006</year>
                <volume>66</volume>
                <fpage>1177</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">16424056</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.lorenzo.2013.507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lorenzo</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ng Tang Fui</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vankayalapati</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhuang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huynh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.</article-title>
                <source>J Mol Med (Berl)</source>
                <year>2013</year>
                <volume>91</volume>
                <fpage>507</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">23090011</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.machens.2006.34">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Machens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.</article-title>
                <source>Mol Cell Endocrinol.</source>
                <year>2006</year>
                <volume>247</volume>
                <fpage>34</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">16343738</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.machens.2001.1104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Machens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinze</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;ppner</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boehm</surname>
                    <given-names>BO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2001</year>
                <volume>86</volume>
                <fpage>1104</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11238493</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.machens.2003.1517">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Machens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niccoli-Sire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoegel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank-Raue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Vroonhoven</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roeher</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahl</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamesch</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte-Devolx</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                  <collab>European Multiple Endocrine Neoplasia (EUROMEN) Study Group</collab>
                </person-group>
                <article-title>Early malignant progression of hereditary medullary thyroid cancer.</article-title>
                <source>N Engl J Med.</source>
                <year>2003</year>
                <volume>349</volume>
                <fpage>1517</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">14561794</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.machens.2004.1083">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Machens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneyer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holzhausen</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.</article-title>
                <source>Surgery.</source>
                <year>2004</year>
                <volume>136</volume>
                <fpage>1083</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15523405</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.mani_.2001.580">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mani&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fusco</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Billaud</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>The RET receptor: function in development and dysfunction in congenital malformation.</article-title>
                <source>Trends Genet.</source>
                <year>2001</year>
                <volume>17</volume>
                <fpage>580</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11585664</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.margraf.2009.548">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Margraf</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crockett</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krautscheid</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seamons</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calderon</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wittwer</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.</article-title>
                <source>Hum Mutat.</source>
                <year>2009</year>
                <volume>30</volume>
                <fpage>548</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">19177457</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.massoll.2004.49">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Massoll</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzaferri</surname>
                    <given-names>EL</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis and management of medullary thyroid carcinoma.</article-title>
                <source>Clin Lab Med.</source>
                <year>2004</year>
                <volume>24</volume>
                <fpage>49</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">15157557</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.menko.2002.393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Menko</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Luijt</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Valk</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toorians</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sepers</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diest</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lips</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <article-title>Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2002</year>
                <volume>87</volume>
                <fpage>393</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11788682</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.miyauchi.1999.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyauchi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Futami</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hai</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokozawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosugi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.</article-title>
                <source>Jpn J Cancer Res.</source>
                <year>1999</year>
                <volume>90</volume>
                <fpage>1</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10076558</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.modigliani.1995.363">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Modigliani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasen</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frilling</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gheri</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandi</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Limbert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederle</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forgas</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg-Bourgin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calmettes</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group.</article-title>
                <source>J Intern Med.</source>
                <year>1995</year>
                <volume>238</volume>
                <fpage>363</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7595173</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.moers.1996.635">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moers</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landsvater</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaap</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen-Schillhorn van Veen</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Valk</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blijham</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;ppener</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vroom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Amstel</surname>
                    <given-names>HK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lips</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <article-title>Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.</article-title>
                <source>Am J Med.</source>
                <year>1996</year>
                <volume>101</volume>
                <fpage>635</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">9003111</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.moley.1998.521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moley</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debenedetti</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dilley</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tisell</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <article-title>Surgical management of patients with persistent or recurrent medullary thyroid cancer.</article-title>
                <source>J Intern Med.</source>
                <year>1998</year>
                <volume>243</volume>
                <fpage>521</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9681853</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.morrison.1996.779">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nevin</surname>
                    <given-names>NC</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome).</article-title>
                <source>J Med Genet.</source>
                <year>1996</year>
                <volume>33</volume>
                <fpage>779</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">8880581</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.mulligan.1994.2163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mulligan</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atti&#x000e9;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyonnet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frilling</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verellen-Dumoulin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Safar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venter</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponder</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1994</year>
                <volume>3</volume>
                <fpage>2163</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7881414</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF86">
              <mixed-citation publication-type="web">National Comprehensive Cancer Network. Guidelines for the treatment of thyroid carcinoma. NCCN Web site. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf">online</ext-link> (registration required). 2015.</mixed-citation>
            </ref>
            <ref id="men2.REF.neumann.2002.1459">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bausch</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McWhinney</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bender</surname>
                    <given-names>BU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franke</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schipper</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klisch</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altehoefer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januszewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munk</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glaesker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Apel</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reineke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walz</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoang-Vu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brauckhoff</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein-Franke</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klose</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maier-Woelfle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pe&#x000e7;zkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szmigielski</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <collab>Freiburg-Warsaw-Columbus Pheochromocytoma Study Group</collab>
                </person-group>
                <article-title>Germ-line mutations in nonsyndromic pheochromocytoma.</article-title>
                <source>N Engl J Med.</source>
                <year>2002</year>
                <volume>346</volume>
                <fpage>1459</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">12000816</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.neumann.2009.3650">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erlic</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boedeker</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermsen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiavi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falcioni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwok</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauters</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lampe</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edelman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benn</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiegand</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasp</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuck</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sevilla</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peczkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubaszek</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pigny</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Learoyd</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Croxson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabolotny</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaremchuk</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Draf</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muresan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenz</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knipping</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strohm</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyckhoff</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matthias</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preuss</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esser</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaftan</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;ver</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fottner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorgulla</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malekpour</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarandy</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schipper</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brase</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glien</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;hnemund</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koscielny</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwerdtfeger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>V&#x000e4;lim&#x000e4;ki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szyfter</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finckh</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ridder</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januszewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suarez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out.</article-title>
                <source>Cancer Res.</source>
                <year>2009</year>
                <volume>69</volume>
                <fpage>3650</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19351833</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.neumann.2004.943">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pawlu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peczkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bausch</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McWhinney</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muresan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franke</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klisch</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bley</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoegerle</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boedeker</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schipper</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januszewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <collab>European-American Paraganglioma Study Group</collab>
                </person-group>
                <article-title>Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.</article-title>
                <source>JAMA</source>
                <year>2004</year>
                <volume>292</volume>
                <fpage>943</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">15328326</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.neumann.2011.e1279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malinoc</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boedeker</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelhardt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walz</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutations of the TMEM127 genes in patients with paraganglioma of the head and neck and extra-adrenal abdominal sites.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>E1279</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">21613359</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.nguyen.2001.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niccoli-Sire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastie</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maes</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohmer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecomte</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henry</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte-Devolx</surname>
                    <given-names>B</given-names>
                  </name>
                  <collab>French Calcitonin Tumors Study Group</collab>
                </person-group>
                <article-title>Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study.</article-title>
                <source>Eur J Endocrinol.</source>
                <year>2001</year>
                <volume>144</volume>
                <fpage>37</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">11174835</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.niccolisire.2003.1029">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Niccoli-Sire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohmer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibelin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte-Devolx</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visset</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronceray</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaeck</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henry</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proye</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carnaille</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraimps</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Groupe D'&#x000e9;tude Des Tumeurs Endocrines. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?</article-title>
                <source>Surgery.</source>
                <year>2003</year>
                <volume>134</volume>
                <fpage>1029</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">14668737</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.nilsson.1999.1587">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tisell</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahlman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.</article-title>
                <source>JAMA</source>
                <year>1999</year>
                <volume>281</volume>
                <fpage>1587</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10235148</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.nunes.2002.5658">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nunes</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ezabella</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krieger</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>SP</given-names>
                  </name>
                </person-group>
                <article-title>A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2002</year>
                <volume>87</volume>
                <fpage>5658</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">12466368</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.pacak.2005.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilias</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eisenhofer</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour.</article-title>
                <source>J Intern Med.</source>
                <year>2005</year>
                <volume>257</volume>
                <fpage>60</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15606377</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.peczkowska.2008.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Peczkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prejbisz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubaszek</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cwik&#x00142;a</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furmanek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erlic</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januszewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <article-title>Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation.</article-title>
                <source>Nat Clin Pract Endocrinol Metab.</source>
                <year>2008</year>
                <volume>4</volume>
                <fpage>111</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18212813</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.pigny.1999.1700">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pigny</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauters</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wemeau</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houcke</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crepin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buisine</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerckaert</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porchet</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>1999</year>
                <volume>84</volume>
                <fpage>1700</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10323403</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.pomares.1998.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pomares</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ca&#x000f1;as</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parrilla</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tebar</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <article-title>Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>1998</year>
                <volume>48</volume>
                <fpage>195</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">9579232</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.pu_ales.2003.2644">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pu&#x000f1;ales</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graf</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maia</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <article-title>RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2003</year>
                <volume>88</volume>
                <fpage>2644</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12788868</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.puxeddu.2003.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Puxeddu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avenia</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cristofani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farabi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reboldi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribacchi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pontecorvi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santeusanio</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.</article-title>
                <source>Eur J Endocrinol.</source>
                <year>2003</year>
                <volume>148</volume>
                <fpage>505</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">12720532</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.qin.2010.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buddavarapu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenci</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chocron</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lechleiter</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sass</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aronin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiavi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boaretto</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stiles</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguiar</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.</article-title>
                <source>Nat Genet.</source>
                <year>2010</year>
                <volume>42</volume>
                <fpage>229</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">20154675</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.raue.2012.20">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rondot</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szpak-Ulczok</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarzab</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank-Raue</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: multiple endocrine neoplasia type 2.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <fpage>20</fpage>
                <pub-id pub-id-type="pmid">21811303</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.rey.2001.390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rey</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brouillet</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonteneau-Allaire</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boneu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basti&#x000e9;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maudelonde</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pujol</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Novel germline RET mutation segregating with papillary thyroid carcinomas.</article-title>
                <source>Genes Chromosomes Cancer.</source>
                <year>2001</year>
                <volume>32</volume>
                <fpage>390</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">11746981</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.robledo.2003.1814">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gil</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll&#x000e1;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cebri&#x000e1;n</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ru&#x000ed;z</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aza&#x000f1;edo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benitez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Men&#x000e1;rguez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rojas</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A.</article-title>
                <source>Cancer Res.</source>
                <year>2003</year>
                <volume>63</volume>
                <fpage>1814</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12702567</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.rodriguez.2008.2520">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balsalobre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponce</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000ed;os</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torregrosa</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tebar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parrilla</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Pheochromocytoma in MEN 2A syndrome. Study of 54 patients.</article-title>
                <source>World J Surg.</source>
                <year>2008</year>
                <volume>32</volume>
                <fpage>2520</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18795243</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.romeo.1998.515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Romeo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceccherini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Celli</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priolo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonardi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jasonni</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martucciello</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Association of multiple endocrine neoplasia type 2 and Hirschsprung disease.</article-title>
                <source>J Intern Med.</source>
                <year>1998</year>
                <volume>243</volume>
                <fpage>515</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">9681852</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.rothberg.2009.651">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rothberg</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sisson</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis.</article-title>
                <source>Thyroid.</source>
                <year>2009</year>
                <volume>19</volume>
                <fpage>651</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19445625</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.ruiz.2001.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruiz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anti&#x000f1;olo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcos</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borrego</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2001</year>
                <volume>55</volume>
                <fpage>399</fpage>
                <lpage>402</lpage>
                <pub-id pub-id-type="pmid">11589684</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.santoro.2004.5448">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melillo</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlomagno</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vecchio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fusco</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Minireview: RET: normal and abnormal functions.</article-title>
                <source>Endocrinology.</source>
                <year>2004</year>
                <volume>145</volume>
                <fpage>5448</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">15331579</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.santoro.2002.370">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papotti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiappetta</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Rostan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volante</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camp</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pentimalli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monaco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrero</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carcangiu</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fusco</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tallini</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>RET activation and clinicopathologic features in poorly differentiated thyroid tumors.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2002</year>
                <volume>87</volume>
                <fpage>370</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11788678</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.schilling.2001.62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schilling</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;rck</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinn</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clemens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;ppner</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herfarth</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwab</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raue</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Prognostic value of codon 918 (ATG--&#x0003e;ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.</article-title>
                <source>Int J Cancer.</source>
                <year>2001</year>
                <volume>95</volume>
                <fpage>62</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11241313</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.schuffenecker.1997.233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schuffenecker</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginet</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldgar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chambe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boneu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houdent</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pallo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlumberger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thivolet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1997</year>
                <volume>60</volume>
                <fpage>233</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">8981969</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.schulte.2010.e92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulte</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fugazzola</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGregor</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diaz-Cano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izatt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylwin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talat</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2010</year>
                <volume>95</volume>
                <fpage>E92</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20554711</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.seri.1997.86">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Celli</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betsos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claudiani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camera</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romeo</surname>
                    <given-names>G. A</given-names>
                  </name>
                </person-group>
                <article-title>Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis.</article-title>
                <source>Clin Genet.</source>
                <year>1997</year>
                <volume>51</volume>
                <fpage>86</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">9111993</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.shifrin.2009.998">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shifrin</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xenachis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fay</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matulewicz</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuo</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernick</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <article-title>One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?</article-title>
                <source>Surgery.</source>
                <year>2009</year>
                <volume>146</volume>
                <fpage>998</fpage>
                <lpage>1005</lpage>
                <pub-id pub-id-type="pmid">19958926</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.skinner.1996.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeBenedetti</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moley</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norton</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>SA</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.</article-title>
                <source>J Pediatr Surg.</source>
                <year>1996</year>
                <volume>31</volume>
                <fpage>177</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">8632274</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.smith.1997.1213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houghton</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponder</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>Germline mutation of RET codon 883 in two cases of de novo MEN 2B.</article-title>
                <source>Oncogene.</source>
                <year>1997</year>
                <volume>15</volume>
                <fpage>1213</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9294615</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.szinnai.2003.e132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Szinnai</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komminoth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zumsteg</surname>
                    <given-names>UW</given-names>
                  </name>
                </person-group>
                <article-title>Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis.</article-title>
                <source>Pediatrics.</source>
                <year>2003</year>
                <volume>111</volume>
                <fpage>E132</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12563086</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.ta_eb.2013.e908">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ta&#x000ef;eb</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delenne</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhuang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebag</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2013</year>
                <volume>98</volume>
                <fpage>E908</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">23539726</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.takahashi.1998.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asai</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.</article-title>
                <source>J Intern Med.</source>
                <year>1998</year>
                <volume>243</volume>
                <fpage>509</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">9681851</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.takahashi.1999.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwashita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyonnet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Billaud</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?</article-title>
                <source>Hum Mutat.</source>
                <year>1999</year>
                <volume>13</volume>
                <fpage>331</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10220148</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.takaya.1996.617">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takaya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshimasa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamura</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakao</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin.</article-title>
                <source>J Mol Med (Berl)</source>
                <year>1996</year>
                <volume>74</volume>
                <fpage>617</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">8912182</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.tallini.1998.287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tallini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlomagno</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvatore</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiappetta</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carcangiu</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fusco</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.</article-title>
                <source>Clin Cancer Res.</source>
                <year>1998</year>
                <volume>4</volume>
                <fpage>287</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">9516913</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.thosani.2013.e1813">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thosani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayala-Ramirez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rich</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waguespack</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habra</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jimenez</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2013</year>
                <volume>98</volume>
                <fpage>E1813</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24030942</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.vandy.2011.805">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vandy</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sisk</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berguer</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Synchronous carotid body and thoracic paraganglioma associated with a germline SDHC mutation.</article-title>
                <source>J Vasc Surg.</source>
                <year>2011</year>
                <volume>53</volume>
                <fpage>805</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21106325</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.verga.2003.156">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verga</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fugazzola</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cambiaghi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pritelli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alessi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cortelazzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gangi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Frequent association between MEN 2A and cutaneous lichen amyloidosis.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2003</year>
                <volume>59</volume>
                <fpage>156</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">12864791</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.welander.2011.r253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Welander</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000f6;derkvist</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.</article-title>
                <source>Endocr Relat Cancer.</source>
                <year>2011</year>
                <volume>18</volume>
                <fpage>R253</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">22041710</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.wells.2013.3149">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>SA</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Pacini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2013</year>
                <volume>98</volume>
                <fpage>3149</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">23744408</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.wray.2008.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wray</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rich</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waguespack</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrier</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <article-title>Failure to recognize multiple endocrine neoplasia 2B: more common than we think?</article-title>
                <source>Ann Surg Oncol.</source>
                <year>2008</year>
                <volume>15</volume>
                <fpage>293</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">17963006</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.yang.2015.93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhuang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fliedner</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shankavaram</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bullova</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elkahloun</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kourlas</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kebebew</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia.</article-title>
                <source>J Mol Med (Berl)</source>
                <year>2015</year>
                <volume>93</volume>
                <fpage>93</fpage>
                <lpage>104</lpage>
                <pub-id pub-id-type="pmid">25263965</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.yao.2010.2611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiavi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inglada-P&#x000e9;rez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ercolino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapizzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricketts</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mori</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giacch&#x000e8;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taschin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boaretto</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iacobone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biondi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lima-Junior</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kater</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bex</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barontini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maher</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opocher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <article-title>Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.</article-title>
                <source>JAMA</source>
                <year>2010</year>
                <volume>304</volume>
                <fpage>2611</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21156949</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.yip.2003.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yip</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayers</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herzog</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sellin</surname>
                    <given-names>RV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagel</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <article-title>Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.</article-title>
                <source>Arch Surg.</source>
                <year>2003</year>
                <volume>138</volume>
                <fpage>409</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">12686527</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.zbuk.2007.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zbuk</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Cancer phenomics: RET and PTEN as illustrative models.</article-title>
                <source>Nat Rev Cancer.</source>
                <year>2007</year>
                <volume>7</volume>
                <fpage>35</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">17167516</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="men2.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="men2.Suggested_Reading.reflist0">
            <ref id="men2.REF.giraud.2001">
              <mixed-citation publication-type="web">Giraud S. Multiple endocrine neoplasia type 2 (MEN2). <italic toggle="yes">Atlas of Genetics and Cytogenetics in Oncology and Haematology</italic>. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://atlasgeneticsoncology.org/Kprones/MEN2ID10009.html">online</ext-link>. 2001. Accessed 6-21-17.</mixed-citation>
            </ref>
            <ref id="men2.REF.machens.2009.114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Machens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dralle</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities.</article-title>
                <source>J Intern Med.</source>
                <year>2009</year>
                <volume>266</volume>
                <fpage>114</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">19522830</pub-id>
              </element-citation>
            </ref>
            <ref id="men2.REF.ponder">
              <mixed-citation publication-type="web">Ponder BAJ. Multiple endocrine neoplasia type 2. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 42. McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="men2.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="men2.Author_History">
          <title>Author History</title>
          <p>Charis Eng, MD, PhD, FACP (2010-present)Jessica Marquard, MS, LGC (2010-present)Georgia L Wiesner, MD, MS, FACMG; Case Western Reserve University School of Medicine (1999-2010)Karen Snow-Bailey, PhD, FACMG, FHGSA; Auckland City Hospital (1999-2006*)</p>
          <p>*Karen Snow-Bailey died on September 10, 2006. The following is excerpted from a tribute by Stephen N Thibodeau, PhD, of the Mayo Clinic, Rochester, MN:</p>
          <p>"Karen was well known to so many of us, as she was an active member of the Association for Molecular Pathology (AMP)....In 1993, Karen joined the medical staff at the Mayo Clinic, where she was responsible for codirecting the Molecular Genetics Laboratory in the Department of Laboratory Medicine and Pathology....In 2002, Karen returned to New Zealand to be closer to family and became an international presence. Importantly, she began to have a tremendous influence in the development of diagnostic genetics services both in New Zealand and Australia....Karen was a scientist, an educator, and an artist....We will all miss Karen as a colleague, as a mentor to many, as an individual who had a vision for the future, but most importantly, as a warm and compassionate friend who cared for others."</p>
          <p>[Reprinted from <italic toggle="yes">J Mol Diagn</italic> 2007, 9:133 with permission from the American Society for Investigative Pathology and the Association for Molecular Pathology]</p>
        </sec>
        <sec id="men2.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 June 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 January 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>4 May 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 March 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 May 2004 (cd) Revision: Genetic Counseling</p>
            </list-item>
            <list-item>
              <p>21 January 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 September 1999 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>October 1998 (gw) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
